<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6134710\results\search\drugs\results.xml">
   <result pre="erythrocytes, 700 μl of viral suspension, supplemented with 5 mM" exact="adenosine" post="triphosphate (ATP), a phagostimulant. Two feeders were prepared per"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6199244\results\search\drugs\results.xml">
   <result pre="the M2 protein, there was no significant substitution associated with" exact="amantadine" post="and rimantadine resistance between the 2017sum and 2016–2017win strains"/>
   <result pre="protein, there was no significant substitution associated with amantadine and" exact="rimantadine" post="resistance between the 2017sum and 2016–2017win strains in either"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6213772\results\search\drugs\results.xml">
   <result pre="for treatmentCurr. Infect. Dis. Rep.20121415516010.1007/s11908-012-0236-x22249425 51.GubarevaL.V.KaiserL.HaydenF.G.Influenza virus neuraminidase inhibitorsLancet200035582783510.1016/S0140-6736(99)11433-810711940 52.JacksonR.J.CooperK.L.TappendenP.ReesA.SimpsonE.L.ReadR.C.NicholsonK.G.Oseltamivir," exact="zanamivir" post="and amantadine in the prevention of influenza: A systematic"/>
   <result pre="Infect. Dis. Rep.20121415516010.1007/s11908-012-0236-x22249425 51.GubarevaL.V.KaiserL.HaydenF.G.Influenza virus neuraminidase inhibitorsLancet200035582783510.1016/S0140-6736(99)11433-810711940 52.JacksonR.J.CooperK.L.TappendenP.ReesA.SimpsonE.L.ReadR.C.NicholsonK.G.Oseltamivir, zanamivir and" exact="amantadine" post="in the prevention of influenza: A systematic reviewJ. Infect.201162142510.1016/j.jinf.2010.10.00320950645"/>
   <result pre="worldwide from 1994 to 2005: A cause for concernLancet20053661175118110.1016/S0140-6736(05)67338-216198766 56.BesselaarT.G.NaidooD.BuysA.GregoryV.McAnerneyJ.ManamelaJ.M.BlumbergL.SchoubB.D.Widespread" exact="oseltamivir" post="resistance in Influenza A viruses (H1N1), south africaEmerg. Infect."/>
   <result pre="Infect. Dis.2008141809181010.3201/eid1411.08095818976580 57.BloomJ.D.GongL.I.BaltimoreD.Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistanceScience20103281272127510.1126/science.118781620522774 58.BakerS.F.NogalesA.Martinez-SobridoL.Downregulating viral gene expression: Codon usage bias manipulation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6249340\results\search\drugs\results.xml">
   <result pre="antivirals have been approved to facilitate influenza treatment. Amantadine and" exact="rimantadine" post="target the IAV M2 proteins, to inhibit uncoating of"/>
   <result pre="to inhibit uncoating of the virus, while oseltamivir, zanamivir, and" exact="peramivir" post="target NA to prevent virus spread (De Clercq, 2006;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6251852\results\search\drugs\results.xml">
   <result pre="CHIKV arthritis [36]. In a previous study, the authors used" exact="hydroxychloroquine" post="(HCQ) to treat patients with chronic CHIK arthritis, with"/>
   <result pre="[28]. A 24-week, two-arm parallel efficacy trial comparing CQ and" exact="meloxicam" post="did not show any significant difference in efficacy between"/>
   <result pre="Ganu et al. found good response with a combination of" exact="sulfasalazine" post="and methotrexate compared to sulfasalazine alone in patients with"/>
   <result pre="al. found good response with a combination of sulfasalazine and" exact="methotrexate" post="compared to sulfasalazine alone in patients with chronic persistent"/>
   <result pre="response with a combination of sulfasalazine and methotrexate compared to" exact="sulfasalazine" post="alone in patients with chronic persistent CHIK arthritis not"/>
   <result pre="for post-acute and chronic CHIK infections with the option of" exact="methotrexate" post="in patients not responding to initial therapy [40]. The"/>
   <result pre="peptide [44]. Other potential drugs with anti-CHIK action are niclosamide," exact="nitazoxanide" post="and suramin, all of which inhibit virus entry, fusion,"/>
   <result pre="arthritis. An open pilot studyS Afr Med J1984662172186087474 37.ChopraASalujaMVenugopalanAEffectiveness of" exact="chloroquine" post="and inflammatory cytokine response in patients with early persistent"/>
   <result pre="chikungunya virus infectionArthritis Rheumatol.20146631932610.1002/art.3822124504804 38.RavindranVinodAliasGeorgeEfficacy of combination DMARD therapy vs." exact="hydroxychloroquine" post="monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized"/>
   <result pre="of a candidate therapeutic autophagy-inducing peptideNature201349420120610.1038/nature1186623364696 45.WangYLuJLinCet al.Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmissionAntiviral Res2016135819010.1016/j.antiviral.2016.10.00327742486"/>
   <result pre="candidate therapeutic autophagy-inducing peptideNature201349420120610.1038/nature1186623364696 45.WangYLuJLinCet al.Antiviral activities of niclosamide and" exact="nitazoxanide" post="against chikungunya virus entry and transmissionAntiviral Res2016135819010.1016/j.antiviral.2016.10.00327742486 46.HoYWangYLuJet al.Suramin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6254586\results\search\drugs\results.xml">
   <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivirAntimicrob Agents Chemother20034772264227212821478 32ShaJChenXRenYet al.Differences in the epidemiology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6264817\results\search\drugs\results.xml">
   <result pre="29/283 (10%) studies described using an anti-malarial agent such as" exact="hydroxychloroquine" post="to treat chikungunya symptoms. A randomized controlled trial examining"/>
   <result pre="chikungunya symptoms. A randomized controlled trial examining the effectiveness of" exact="chloroquine" post="to treat chikungunya concluded that there is no justification"/>
   <result pre="ReynierJC, EnaultS, CharrelRN, FlahaultA, et al.On chikungunya acute infection and" exact="chloroquine" post="treatment. Vector Borne and Zoonotic Diseases2008;8(6):837–840. 10 ref. 10.1089/vbz.2008.004918620511"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6293039\results\search\drugs\results.xml">
   <result pre="a headache, and abdominal pain (Figure 1). She was given" exact="paracetamol" post="and an antimalarial (artemether-lumefantrine) and was seen at 2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6293476\results\search\drugs\results.xml">
   <result pre="and treated with SR9009 at 1 hpi. At 23 hpi," exact="puromycin" post="was added to the culture supernatant at a final"/>
   <result pre="the presence of SR9009 or DMSO, and at 23 hpi," exact="puromycin" post="was added to the culture media for 1 hour"/>
   <result pre="for 1 hour before harvesting whole-cell lysates. Mock-infected cells incorporated" exact="puromycin" post="efficiently, whereas puromycin detection in infected cells was drastically"/>
   <result pre="before harvesting whole-cell lysates. Mock-infected cells incorporated puromycin efficiently, whereas" exact="puromycin" post="detection in infected cells was drastically reduced (Figure 1D),"/>
   <result pre="of viral capsid protein, there was no proportional increase in" exact="puromycin" post="detection. These results show that the early events of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6372163\results\search\drugs\results.xml">
   <result pre="penicillin (100 U/ml; Sigma-Aldrich, Saint Louis, MO, United States), and" exact="streptomycin" post="(100 μg/ml; Sigma-Aldrich). Prior to infections in the BSL3"/>
   <result pre="(HEPES-DMEM; Gibco) supplemented with 10% FBS, penicillin (100 U/ml), and" exact="streptomycin" post="(100 μg/ml), fungizone (50 μg/ml; Invitrogen, Carlsbad, United States),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6373151\results\search\drugs\results.xml">
   <result pre="recovery, creatine phosphate sodium for providing heart muscle energy, methyl" exact="prednisolone" post="for reducing inflammation and cerebral edema, and potassium sodium"/>
   <result pre="drographolide succinate as antiviral therapy. The patient was also administered" exact="midazolam" post="(5 mg) twice daily on days 1 and 2 after"/>
   <result pre="We also found that in the treatment of severe HFMD," exact="milrinone" post="in combination with hydrochloride esmolol helps reduce the heart"/>
   <result pre="the treatment of severe HFMD, milrinone in combination with hydrochloride" exact="esmolol" post="helps reduce the heart rate and maintain cardiopulmonary function."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6373929\results\search\drugs\results.xml">
   <result pre="°C. Wells were then overlaid with 1 ml of 0.8%" exact="methylcellulose" post="(Sigma-Aldrich, St. Louis) diluted in warm Optimem (Invitrogen) supplemented"/>
   <result pre="a cell culture-derived virus stock supplemented with 21% FBS, and" exact="adenosine" post="triphosphate (ATP) to a final concentration of 0.005 M"/>
   <result pre="of Bacto Tryptose Phosphate Broth) supplemented with 21% FBS, and" exact="adenosine" post="triphosphate (ATP) to a final concentration of 0.005 M"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6375641\results\search\drugs\results.xml">
   <result pre="Station at Bakersfield, treated with 0.2 mg per mL of" exact="chlortetracycline" post="(Fort Dodge, Overland Park, KS) for two weeks, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6391539\results\search\drugs\results.xml">
   <result pre="and pro-inflammatory responses. Vet Res2014; 45: 118.25431115 58BurggraafSBinghamJPayneJet al.Increased inducible" exact="nitric oxide" post="synthase expression in organs is associated with a higher"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6409754\results\search\drugs\results.xml">
   <result pre="viral replicationChemMedChem201272227223510.1002/cmdc.20120045323139022 198.BloomJ.D.GongL.I.BaltimoreD.Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistanceScience20103281272127510.1126/science.118781620522774 199.BloomJ.D.NayakJ.S.BaltimoreD.A computational-experimental approach identifies mutations that enhance surface"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6410217\results\search\drugs\results.xml">
   <result pre="of laboratory confirmation is crucial. According to the WHO guidelines," exact="paracetamol" post="is the first-line analgesic treatment, and aspirin or other"/>
   <result pre="213.KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of in vitro prophylactic and therapeutic efficacy of" exact="chloroquine" post="against chikungunya virus in vero cellsJ. Med. Virol.20108281782410.1002/jmv.2166320336760 214.RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de"/>
   <result pre="in vero cellsJ. Med. Virol.20108281782410.1002/jmv.2166320336760 214.RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.et al.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses20181026810.3390/v10050268 215.SmithS.A.SilvaL.A.FoxJ.M.FlyakA.I.KoseN.SapparapuG.KhomandiakS.AshbrookA.W.KahleK.M.FongR.H.et al.Isolation and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6429326\results\search\drugs\results.xml">
   <result pre="future perspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 109.SacramentoC.Q.De MeloG.R.De FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.J.S.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 110.DelvecchioR.HigaL.M.PezzutoP.ValadãoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.Chloroquine, an endocytosis blocking"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6455116\results\search\drugs\results.xml">
   <result pre="allosteric inhibitor of Hsp70 that preferentially binds and inhibits the" exact="adenosine" post="diphosphate (ADP) bound forms of Hsp70 [24]. To investigate"/>
   <result pre="with 10% fetal bovine serum (FBS; Invitrogen), 1X penicillin and" exact="streptomycin" post="(Invitrogen) and 2 mM L-glutamine (Invitrogen). The MR766 ZIKV strain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6455256\results\search\drugs\results.xml">
   <result pre="308667621559709 doi: 10.1080/22221751.2018.1559709 : Article The clinically licensed antifungal drug" exact="itraconazole" post="inhibits influenza virus in vitro and in vivo Emerging"/>
   <result pre="this study, we describe the use of the antifungal therapeutics" exact="posaconazole" post="and itraconazole in the therapy of IAV. We show"/>
   <result pre="we describe the use of the antifungal therapeutics posaconazole and" exact="itraconazole" post="in the therapy of IAV. We show that both"/>
   <result pre="the induced imbalance of cellular cholesterol. The antiviral effect of" exact="itraconazole" post="could be confirmed in the mouse model, where the"/>
   <result pre="be confirmed in the mouse model, where the administration of" exact="itraconazole" post="led to a drastic reduction in mortality and a"/>
   <result pre="our data indicate a promising therapeutic potential of at least" exact="itraconazole" post="in influenza therapy. KEYWORDS Influenza A virus posaconazole itraconazole"/>
   <result pre="at least itraconazole in influenza therapy. KEYWORDS Influenza A virus" exact="posaconazole" post="itraconazole interferon response cellular cholesterol host cell factors mouse"/>
   <result pre="least itraconazole in influenza therapy. KEYWORDS Influenza A virus posaconazole" exact="itraconazole" post="interferon response cellular cholesterol host cell factors mouse model"/>
   <result pre="the antiviral capability of two well-studied, systemic triazole derivate drugs" exact="itraconazole" post="and posaconazole [10,20]. These drugs display antifungal activity due"/>
   <result pre="capability of two well-studied, systemic triazole derivate drugs itraconazole and" exact="posaconazole" post="[10,20]. These drugs display antifungal activity due to the"/>
   <result pre="IBV subtypes in vitro and in vivo. Results Itraconazole and" exact="posaconazole" post="inhibit the propagation of IAV and VSV To evaluate"/>
   <result pre="VSV To evaluate a potential antiviral activity of the antifungals" exact="itraconazole" post="and posaconazole, we measured the relationship between drug dose"/>
   <result pre="exposed for 24 h to solvent DMSO, or increasing concentrations of" exact="itraconazole" post="and posaconazole. As shown in Figure 1(B), staurosporine, a"/>
   <result pre="massive cell death, while neither DMSO nor any of the" exact="itraconazole" post="and posaconazole concentrations tested reduced the cellular viability in"/>
   <result pre="death, while neither DMSO nor any of the itraconazole and" exact="posaconazole" post="concentrations tested reduced the cellular viability in a significant"/>
   <result pre="IAV propagation. In order to explore the antiviral potential of" exact="itraconazole" post="and posaconazole further, we infected A549 cells and the"/>
   <result pre="In order to explore the antiviral potential of itraconazole and" exact="posaconazole" post="further, we infected A549 cells and the human skin"/>
   <result pre="high virus titres 24 h p.i. in DMSO-treated control cells. Importantly," exact="itraconazole" post="pretreatment for 16 h significantly reduced viral titers for both"/>
   <result pre="(0.1 MOI), although the effect was less pronounced. Pretreatment with" exact="posaconazole" post="was not as effective as itraconazole pretreatment, and both"/>
   <result pre="less pronounced. Pretreatment with posaconazole was not as effective as" exact="itraconazole" post="pretreatment, and both IAV and VSV infections were inhibited"/>
   <result pre="the exemplary IAV strains PR8M was also successfully inhibited upon" exact="itraconazole" post="treatment, whereas both drugs could block infection with the"/>
   <result pre="IBV strain B/Lee/1940 (Suppl. Fig. S1). Figure 1. The antifungals" exact="itraconazole" post="and posaconazole block IAV infection at non-cytotoxic concentrations. (A)"/>
   <result pre="B/Lee/1940 (Suppl. Fig. S1). Figure 1. The antifungals itraconazole and" exact="posaconazole" post="block IAV infection at non-cytotoxic concentrations. (A) Dose–response curve"/>
   <result pre="block IAV infection at non-cytotoxic concentrations. (A) Dose–response curve of" exact="itraconazole" post="and posaconazole in A549 cells. Cells were treated with"/>
   <result pre="infection at non-cytotoxic concentrations. (A) Dose–response curve of itraconazole and" exact="posaconazole" post="in A549 cells. Cells were treated with either DMSO,"/>
   <result pre="posaconazole in A549 cells. Cells were treated with either DMSO," exact="posaconazole" post="(Posa) or itraconazole (Itra) for 16 h, and subsequently infected"/>
   <result pre="cells. Cells were treated with either DMSO, posaconazole (Posa) or" exact="itraconazole" post="(Itra) for 16 h, and subsequently infected with IAV strain"/>
   <result pre="IAV strain PR8M (MOI = 0.1). Virus titers were converted to percentages," exact="posaconazole" post="and itraconazole concentrations were log-transformed, and EC50 and EC90"/>
   <result pre="PR8M (MOI = 0.1). Virus titers were converted to percentages, posaconazole and" exact="itraconazole" post="concentrations were log-transformed, and EC50 and EC90 values were"/>
   <result pre="either the protein kinase inhibitor staurosporine (St), the solvent DMSO," exact="itraconazole" post="(Itra) or posaconazole (Posa) at the indicated concentrations for"/>
   <result pre="kinase inhibitor staurosporine (St), the solvent DMSO, itraconazole (Itra) or" exact="posaconazole" post="(Posa) at the indicated concentrations for 24 h. Data represent"/>
   <result pre="A549, A431 cells or HUVECs were treated with either DMSO," exact="posaconazole" post="(Posa) or itraconazole (Itra) for 16 h, and subsequently infected"/>
   <result pre="or HUVECs were treated with either DMSO, posaconazole (Posa) or" exact="itraconazole" post="(Itra) for 16 h, and subsequently infected with the indicated"/>
   <result pre="with Dunnett’s multiple comparison tests, ****p ≤ 0.0001;***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05. Itraconazole and" exact="posaconazole" post="treatment primes the interferon response To determine whether the"/>
   <result pre="the IFN response is involved in the antiviral capability of" exact="itraconazole" post="and posaconazole, we employed Vero cells which are genetically"/>
   <result pre="of the IFN system in mediating an antiviral effect of" exact="itraconazole" post="and posaconazole. Because both antifungals elicited a more prominent"/>
   <result pre="3(B), IFNα mRNA levels were moderately, albeit significantly elevated upon" exact="itraconazole" post="and posaconazole treatment, whereas IFNβ levels were only altered"/>
   <result pre="mRNA levels were moderately, albeit significantly elevated upon itraconazole and" exact="posaconazole" post="treatment, whereas IFNβ levels were only altered upon itraconazole"/>
   <result pre="and posaconazole treatment, whereas IFNβ levels were only altered upon" exact="itraconazole" post="treatment. Notably, we confirmed that the enhanced basal expression"/>
   <result pre="infected cells, indicating a drug-induced priming. Figure 3. Itraconazole and" exact="posaconazole" post="prime the IFN response. (A) PR8M and PAN virus"/>
   <result pre="the IFN response. (A) PR8M and PAN virus titers upon" exact="posaconazole" post="(Posa) and itraconazole (Itra) treatment of IFN-insensitive Vero cells."/>
   <result pre="(A) PR8M and PAN virus titers upon posaconazole (Posa) and" exact="itraconazole" post="(Itra) treatment of IFN-insensitive Vero cells. (B, C) qPCR"/>
   <result pre="(C) PR8M-infected A549 cells after 16 h treatment with either DMSO," exact="itraconazole" post="(Itra) or posaconazole (Posa). Samples were obtained from at"/>
   <result pre="cells after 16 h treatment with either DMSO, itraconazole (Itra) or" exact="posaconazole" post="(Posa). Samples were obtained from at least seven independent"/>
   <result pre="tests on ΔΔCt values. ****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05. Itraconazole and" exact="posaconazole" post="negatively affect IAV propagation within the first replication cycle"/>
   <result pre="IAV propagation within the first replication cycle To examine if" exact="itraconazole" post="and posaconazole affect an early step in IAV infection,"/>
   <result pre="within the first replication cycle To examine if itraconazole and" exact="posaconazole" post="affect an early step in IAV infection, we performed"/>
   <result pre="percentage (14%) of cells were NP-positive when pretreated with either" exact="itraconazole" post="or posaconazole (Figure 4(A)). In accordance with the data"/>
   <result pre="of cells were NP-positive when pretreated with either itraconazole or" exact="posaconazole" post="(Figure 4(A)). In accordance with the data presented above,"/>
   <result pre="cycle, independently of the IFN response. Figure 4. Itraconazole and" exact="posaconazole" post="impair an early step in the IAV infection cycle."/>
   <result pre="IAV infection cycle. Cells pretreated with either the solvent DMSO," exact="posaconazole" post="(Posa), or itraconazole (Itra) for 16 h were infected with"/>
   <result pre="Cells pretreated with either the solvent DMSO, posaconazole (Posa), or" exact="itraconazole" post="(Itra) for 16 h were infected with PR8M at the"/>
   <result pre="*p ≤ 0.05; one-way ANOVA followed by Dunnett’s multiple comparison test. Both" exact="itraconazole" post="and posaconazole have been shown to inhibit cholesterol export"/>
   <result pre="ANOVA followed by Dunnett’s multiple comparison test. Both itraconazole and" exact="posaconazole" post="have been shown to inhibit cholesterol export from the"/>
   <result pre="a general change in cellular cholesterol. Figure 5. Itraconazole and" exact="posaconazole" post="induce endolysosomal cholesterol storage without affecting endolysosomal acidification. (A)"/>
   <result pre="A549 cells treated for 16 h with either the solvent DMSO," exact="posaconazole" post="(Posa), or itraconazole (Itra) were stained for the LE/L"/>
   <result pre="for 16 h with either the solvent DMSO, posaconazole (Posa), or" exact="itraconazole" post="(Itra) were stained for the LE/L marker protein CD63."/>
   <result pre="(C) Cholesterol levels in cells treated with the solvent DMSO," exact="posaconazole" post="(Posa), or itraconazole (Itra). Data are expressed as mean"/>
   <result pre="in cells treated with the solvent DMSO, posaconazole (Posa), or" exact="itraconazole" post="(Itra). Data are expressed as mean cholesterol concentrations (in"/>
   <result pre="vRNPs into the host cell nucleus. Figure 6. Effects of" exact="itraconazole" post="and posaconazole on IAV infectivity under acidic bypass conditions."/>
   <result pre="the host cell nucleus. Figure 6. Effects of itraconazole and" exact="posaconazole" post="on IAV infectivity under acidic bypass conditions. Cells were"/>
   <result pre="bypass conditions. Cells were pretreated with either the solvent DMSO," exact="posaconazole" post="(Posa) or itraconazole (Itra) for 16 h, and were infected"/>
   <result pre="were pretreated with either the solvent DMSO, posaconazole (Posa) or" exact="itraconazole" post="(Itra) for 16 h, and were infected with IAV (PR8M,"/>
   <result pre="multiple comparison test. Itraconazole improves survival upon IAV infection Because" exact="itraconazole" post="showed a more pronounced antiviral effect in the cell"/>
   <result pre="human. Thus, mice that had received an intragastrical application of" exact="itraconazole" post="(70 mg/kg body weight) or vehicle the day before were"/>
   <result pre="infection (Figure 7(A). To further examine the protective role of" exact="itraconazole" post="in the host defense against IAV, we surveyed the"/>
   <result pre="Figure S5) at d3, d5, and d7 p.i., confirming that" exact="itraconazole" post="could effectively control the spread of IAV infection. To"/>
   <result pre="indicate a therapeutic potential of at least the antifungal drug" exact="itraconazole" post="in the treatment of IAV infections. Figure 7. Itraconazole"/>
   <result pre="in mice. Eight-to-ten weeks-old male mice were treated intragastrically with" exact="itraconazole" post="(70 mg/kg body weight) diluted in propylene glycol hydroxypropyl-β-cyclodextrine (Itra,"/>
   <result pre="present study, we investigated the use of the antifungal drugs" exact="itraconazole" post="and posaconazole in the treatment of IAV infection. As"/>
   <result pre="we investigated the use of the antifungal drugs itraconazole and" exact="posaconazole" post="in the treatment of IAV infection. As expected with"/>
   <result pre="host cell response. However, the unaltered cholesterol contents detected in" exact="itraconazole" post="and posaconazole-treated cells suggest that the antiviral effect is"/>
   <result pre="not due to a disturbed cellular cholesterol biosynthesis. Of note," exact="itraconazole" post="was identified as a small molecule inhibitor of the"/>
   <result pre="of a wide range of viruses [10–14]. In this regard," exact="itraconazole" post="was shown to function as a broad-spectrum inhibitor for"/>
   <result pre="drugs, which might contribute to the observed inhibitory effect of" exact="itraconazole" post="on IAV infection. However, we cannot exclude that the"/>
   <result pre="escape and a weak priming of the IFN response. Importantly," exact="itraconazole" post="reduced IAV infection in vivo in the mouse model."/>
   <result pre="for a 60 kg human. As the recommended daily dose of" exact="itraconazole" post="for therapy of fungal infections is 200–400 mg/day, and might"/>
   <result pre="study, which not only reports an inhibitory effect of both" exact="itraconazole" post="and posaconazole in cell culture but shows an efficient"/>
   <result pre="not only reports an inhibitory effect of both itraconazole and" exact="posaconazole" post="in cell culture but shows an efficient itraconazole-mediated reduction"/>
   <result pre="humidified incubator at 37°C and 5% CO2. Itraconazole (Sigma) and" exact="posaconazole" post="(Sigma) were solubilized in DMSO at 2 mg/ml. Prior to"/>
   <result pre="2 mg/ml. Prior to infection, cells were treated with 2 µg/ml" exact="itraconazole" post="or posaconazole for 16 h, or with 250 nM Bafilomycin A1"/>
   <result pre="to infection, cells were treated with 2 µg/ml itraconazole or" exact="posaconazole" post="for 16 h, or with 250 nM Bafilomycin A1 (Cayman-Cay-11038) for"/>
   <result pre="Bafilomycin A1 (Cayman-Cay-11038) for 2 h. For postinfection treatment, 2 µg/ml" exact="itraconazole" post="or posaconazole were added 2 h postinfection. Cytotoxicity assay A549"/>
   <result pre="(Cayman-Cay-11038) for 2 h. For postinfection treatment, 2 µg/ml itraconazole or" exact="posaconazole" post="were added 2 h postinfection. Cytotoxicity assay A549 cells were"/>
   <result pre="(LANUV, 84-02.04.2016.A426). Eight-to-ten weeks-old male animals were treated intragastrically with" exact="itraconazole" post="(70 mg/kg body weight) diluted in propylene glycol hydroxypropyl-β-cyclodextrine. Human"/>
   <result pre="the equivalent volume of the solvent. Mice were anesthetized with" exact="isoflurane" post="prior to intranasal infection with 500 pfu (plaque forming units)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6456646\results\search\drugs\results.xml">
   <result pre="was also tested in eight patients who received interferon and" exact="ribavirin" post="treatment of which six patients were completely cured of"/>
   <result pre="the gut microbiota is associated with HIV disease progression and" exact="tryptophan" post="catabolism. Sci. Transl. Med.5:193ra91. 10.1126/scitranslmed.300643823843452 WangH. B.MoQ. H.YangZ. (2015)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6465516\results\search\drugs\results.xml">
   <result pre="less prone to get infected. Moreover, the macrolide antibiotic drug" exact="azithromycin" post="can potentially protect brain cells from ZIKV infection by"/>
   <result pre="Care STDS. (2013) 27:5–16. 10.1089/apc.2012.032923305257 SetoW-KHuiAJWongVW-SWongGL-HLiuKS-HLaiC-Let al.. Treatment cessation of" exact="entecavir" post="in Asian patients with hepatitis B e antigen negative"/>
   <result pre="in Chinese chronic hepatitis B patients after 5 years of" exact="entecavir" post="treatment. J Gastroenterol Hepatol. (2014) 29:1028–34. 10.1111/jgh.1247624325451 MolinaPZapataFCaballeroA. Anion"/>
   <result pre="interactions. Chem Rev. (2017) 117:9907–72. 10.1021/acs.chemrev.6b0081428665114 MolinaJ-MCahnPGrinsztejnBLazzarinAMillsASaagMet al.. Rilpivirine versus" exact="efavirenz" post="with tenofovir and emtricitabine in treatment-naive adults infected with"/>
   <result pre="Rev. (2017) 117:9907–72. 10.1021/acs.chemrev.6b0081428665114 MolinaJ-MCahnPGrinsztejnBLazzarinAMillsASaagMet al.. Rilpivirine versus efavirenz with" exact="tenofovir" post="and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO):"/>
   <result pre="117:9907–72. 10.1021/acs.chemrev.6b0081428665114 MolinaJ-MCahnPGrinsztejnBLazzarinAMillsASaagMet al.. Rilpivirine versus efavirenz with tenofovir and" exact="emtricitabine" post="in treatment-naive adults infected with HIV-1 (ECHO): a phase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6466003\results\search\drugs\results.xml">
   <result pre="Paisley, Scotland) supplemented with 100 U/mL penicillin and 100 μg/mL" exact="streptomycin" post="mixture (Lonza, Cologne, Germany), 2 mM l-glutamine, 10% fetal"/>
   <result pre="in DMEM-F12 supplemented with 100 U/mL penicillin and 100 μg/mL" exact="streptomycin" post="mixture, 2 mM l-glutamine, 10% FBS, and 0.25% sodium"/>
   <result pre="St. Louis, USA) and 100 U/mL penicillin and 100 μg/mL" exact="streptomycin" post="mixture at 37 °C and 5% CO2 for 7"/>
   <result pre="online: http://www.who.int/influenza/gisrs_laboratory/flunet/en/(accessed on 10 October 2018) 15.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infectionJ. Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 16.PirhonenJ.SarenevaT.KurimotoM.JulkunenI.MatikainenS.Virus infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6466125\results\search\drugs\results.xml">
   <result pre="the A group antigen. Both glycans interact with a conserved" exact="tryptophan" post="(375) and common hydrogen binding patterns with both glycans."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6466164\results\search\drugs\results.xml">
   <result pre="(CD4C/rtTA X TRE/HIVNef) or (CD4C/rtTA2S-M2 X TRE/HIVNef) double-Tg mice upon" exact="doxycycline" post="(DOX) treatment, and these mice developed disease similar to"/>
   <result pre="a promoter that can be induced by drugs such as" exact="tetracycline" post="or doxycycline. Then, Cre can activate the expression of"/>
   <result pre="virus serotypes in AG129 mouse models: Proof-of-concept studies with the" exact="adenosine" post="nucleoside inhibitor NITD-008Antivir. Res.201815410410910.1016/j.antiviral.2018.04.01229665374 108.OrozcoS.SchmidM.A.ParameswaranP.LachicaR.HennM.R.BeattyR.HarrisE.Characterization of a model of"/>
   <result pre="CD4C/rtTA × TRE/HIVNef) or (CD4C/rtTA2S-M2 × TRE/HIVNef) double-Tg mice upon" exact="doxycycline" post="(DOX) HIV Nef gene Cellular and molecular pathways of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6466451\results\search\drugs\results.xml">
   <result pre="the main hypotheses of CCA pathogenesis, some of which support" exact="methotrexate" post="(MTX) treatment which has been shown to be effective"/>
   <result pre="preliminary studies in CCA. chikungunya virus chronic chikungunya arthritis pathogenesis" exact="methotrexate" post="1. Introduction Chikungunya virus (CHIKV) is a small (60–70"/>
   <result pre="with NSAIDs, a variety of inflammation suppressing therapies, including corticosteroids," exact="chloroquine" post="(CHQ), hydroxychloroquine (HCQ), sulfasalazine (SSZ), methotrexate (MTX), and immune-modulating"/>
   <result pre="a variety of inflammation suppressing therapies, including corticosteroids, chloroquine (CHQ)," exact="hydroxychloroquine" post="(HCQ), sulfasalazine (SSZ), methotrexate (MTX), and immune-modulating biologic agents"/>
   <result pre="of inflammation suppressing therapies, including corticosteroids, chloroquine (CHQ), hydroxychloroquine (HCQ)," exact="sulfasalazine" post="(SSZ), methotrexate (MTX), and immune-modulating biologic agents including anti-TNF"/>
   <result pre="suppressing therapies, including corticosteroids, chloroquine (CHQ), hydroxychloroquine (HCQ), sulfasalazine (SSZ)," exact="methotrexate" post="(MTX), and immune-modulating biologic agents including anti-TNF agents, B-lymphocyte"/>
   <result pre="of polyamines, reduction of antigen-dependent T-cell proliferation, and promotion of" exact="adenosine" post="release with adenosine-mediated suppression of inflammation [77,78]. In RA,"/>
   <result pre="MTX seem to be related to an extracellular increase in" exact="adenosine" post="and its interaction with specific cell surface receptors. This"/>
   <result pre="and that the accumulation of AICAR is associated with increased" exact="adenosine" post="release in inflammatory exudates; adenosine mediates the anti-inflammatory effects"/>
   <result pre="AICAR is associated with increased adenosine release in inflammatory exudates;" exact="adenosine" post="mediates the anti-inflammatory effects of MTX in animal models"/>
   <result pre="randomized clinical trial comparing MTX monotherapy to MTX combined with" exact="sulfasalazine" post="and hydroxychloroquine. Based on our review of published studies"/>
   <result pre="also had arthritis. The patients received MTX 7.5 mg/week with" exact="folic acid," post="with dose escalations for refractory symptoms at 4 weeks."/>
   <result pre="Jt. Dis.20076516817317922664 78.SwierkotJ.SzechinskiJ.Methotrexate in rheumatoid arthritisPharmacol. Rep.20065847349216963793 79.CutoloM.Anti-inflammatory mechanisms of" exact="methotrexate" post="in rheumatoid arthritisAnn. Rheum. Dis.20016072973510.1136/ard.60.8.72911454634 80.WesselsJ.A.HuizingaT.W.GuchelaarH.Recent insights in the"/>
   <result pre="arthritisAnn. Rheum. Dis.20016072973510.1136/ard.60.8.72911454634 80.WesselsJ.A.HuizingaT.W.GuchelaarH.Recent insights in the pharmacological actions of" exact="methotrexate" post="in the treatment of rheumatoid arthritisRheumatology (Oxford).20074724925510.1093/rheumatology/kem27918045808 81.MontesinosM.C.YapJ.S.DesaiA.PosadasI.McCraryC.T.CronsteinB.N.Reversal of"/>
   <result pre="of rheumatoid arthritisRheumatology (Oxford).20074724925510.1093/rheumatology/kem27918045808 81.MontesinosM.C.YapJ.S.DesaiA.PosadasI.McCraryC.T.CronsteinB.N.Reversal of the antiinflammatory effects of" exact="methotrexate" post="by the nonselective adenosine receptor antagonists theophylline and caffeine:"/>
   <result pre="81.MontesinosM.C.YapJ.S.DesaiA.PosadasI.McCraryC.T.CronsteinB.N.Reversal of the antiinflammatory effects of methotrexate by the nonselective" exact="adenosine" post="receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory"/>
   <result pre="antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of" exact="methotrexate" post="are mediated via multiple adenosine receptors in rat adjuvant"/>
   <result pre="that the antiinflammatory effects of methotrexate are mediated via multiple" exact="adenosine" post="receptors in rat adjuvant arthritisArthritis Rheum.20004365666310728760 82.BedouiY.GiryC.Jaffar-BandjeeM.SelambaromJ.GuiraudP.GasqueP.Immunomodulatory drug methotrexate"/>
   <result pre="multiple adenosine receptors in rat adjuvant arthritisArthritis Rheum.20004365666310728760 82.BedouiY.GiryC.Jaffar-BandjeeM.SelambaromJ.GuiraudP.GasqueP.Immunomodulatory drug" exact="methotrexate" post="used to treat patients with chronic inflammatory rheumatisms post-chikungunya"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6473099\results\search\drugs\results.xml">
   <result pre="LL-37 – Reduced morbidity and mortality to similar levels as" exact="zanamivir" post="in mice. – Mouse-adapted laboratory IAV (H1N1) (21) Influenza"/>
   <result pre="morbidity and mortality to similar levels as the neuraminidase inhibitor" exact="zanamivir" post="that is used for the treatment of human influenza"/>
   <result pre="H1N1 IAV; interestingly, this inhibitor significantly out-performed the clinically recommended" exact="oseltamivir" post="in these studies (26). Another central regulator of immune"/>
   <result pre="virion uncoating (28). Although in vivo inhibition of GRK2 using" exact="paroxetine" post="led to a significant reduction in upper respiratory tract"/>
   <result pre="IAV infected mice (31). Prophylactic treatment of H1N1-infected mice with" exact="pioglitazone" post="(PPARγ agonist) resulted in increased survival (32). Combined activation"/>
   <result pre="Clin Invest. (2013) 123:206–14. 10.1172/JCI6166723202729 31.BuddAAllevaLAlsharifiMKoskinenASmytheVMullbacherAet al.. Increased survival after" exact="gemfibrozil" post="treatment of severe mouse influenza. Antimicrob Agents Chemother. (2007)"/>
   <result pre="Res. (2011) 92:195–203. 10.1016/j.antiviral.2011.08.00221854809 61.HaasbachEHartmayerCPlanzO. Combination of MEK inhibitors and" exact="oseltamivir" post="leads to synergistic antiviral effects after influenza A virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6476056\results\search\drugs\results.xml">
   <result pre="identified risk 1 (7) 3 (13) Drug use Heroin and" exact="methamphetamine" post="10 (71) 12 (52) Heroin without methamphetamine 0 (—)"/>
   <result pre="use Heroin and methamphetamine 10 (71) 12 (52) Heroin without" exact="methamphetamine" post="0 (—) 1 (4) Methamphetamine without heroin 2 (14)"/>
   <result pre="Outbreak Investigation Team. HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014–2015.N Engl J Med2016;375:229–39. 10.1056/NEJMoa151519527468059 2. Kosakovsky"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6504036\results\search\drugs\results.xml">
   <result pre="made to consider a possible treatment-induced decrease in fever (e.g." exact="paracetamol" post="intake during the hours prior to emergency department admission)."/>
   <result pre="Clin Microbiol. 201927;57(3). 40DixitR, KhandakerG, IlgoutzS, RashidH, BooyR. Emergence of" exact="oseltamivir" post="resistance: control and management of influenza before, during and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6514695\results\search\drugs\results.xml">
   <result pre="silybin A and silybin B (1:1) is also known as" exact="silibinin" post="(C25H22O10, PubChem CID: 31553; Figure 1), which makes up"/>
   <result pre="et al. in 2013 showed that the major bioactive component" exact="silibinin" post="exerts antiviral effect against HCV by blocking clathrin-mediated endocytosis"/>
   <result pre="blocking clathrin-mediated endocytosis [12]. Another study in 2013 indicated that" exact="silibinin" post="impedes HCV infection by targeting the HCV NS4B protein"/>
   <result pre="morphogenesis of the viral replication sites. More recently, we developed" exact="silibinin" post="nanoparticles (SB-NPs) and showed that both the SB-NPs and"/>
   <result pre="(SB-NPs) and showed that both the SB-NPs and the conventional" exact="silibinin" post="inhibited HCV infection by blocking viral cell-to-cell spread [15]."/>
   <result pre="that the oral and intravenous (i.e., Legalon® SIL) formulations of" exact="silibinin" post="exert different effects on HCV life cycle, inflammation, and"/>
   <result pre="identified nine phytochemicals possessing potential inhibitory effects against NS4B, including" exact="silibinin" post="and other compounds from the plant S. marianum [18]."/>
   <result pre="from the plant S. marianum [18]. This result suggests that" exact="silibinin" post="could potentially inhibit DENV viral replication. Given that molecular"/>
   <result pre="this important pathogen is highly envisaged. Gazák et al. developed" exact="silibinin" post="derivatives that were conjugated with long-chain fatty acids and"/>
   <result pre="and demonstrated their superior anti-influenza virus activity compared to conventional" exact="silibinin" post="in plaque reduction assay [21]. Later, using cytopathic effect"/>
   <result pre="Interestingly, this finding is compatible with the accumulation of free" exact="silibinin" post="in lung after oral administration that others and we"/>
   <result pre="its ability to block HIV entry. Thus, it appears that" exact="silibinin" post="could simultaneously block HIV entry and T-cell activation. Combined"/>
   <result pre="needed. Recently, Umetsu et al. demonstrated that similar to HCV," exact="silibinin" post="inhibited HBV entry into the permissive HepG2-NTCP-C4 and PXB"/>
   <result pre="interaction, replication or release [31]. More importantly, the combination of" exact="silibinin" post="and Entecavir, a known nucleoside reverse transcriptase inhibitor, reduced"/>
   <result pre="studies have evaluated the effect of silymarin or its component" exact="silibinin" post="in patients with chronic hepatitis C. Oral administration of"/>
   <result pre="12-month silybin-vitamin E-phospholipid complex pills supplemented to pegylated-interferon (Peg-IFN) +" exact="ribavirin" post="(RBV) treatment achieved lower viral load compared to those"/>
   <result pre="difference between these results may imply the importance of improving" exact="silibinin" post="or silybin’s solubility to enhance its effect in clinical"/>
   <result pre="the use of other solvents such as ethanol, glyceryl monooleate," exact="polysorbate" post="20, and transcutol may help increase its solubility ranging"/>
   <result pre="in addressing the solubility and bioavailability issue of the standardized" exact="silibinin" post="(silybin isomers). Specifically, silibinin-loaded nanoparticles (SB-NP) with diameters &amp;lt;200"/>
   <result pre="carrier polyvinylpyrrolidone (PVP), which resulted in the transition of the" exact="silibinin" post="crystalline structure into an amorphous state in the SB-NP"/>
   <result pre="SB-NP and demonstrated a significantly enhanced solubility [15]. Interestingly, free" exact="silibinin" post="was efficiently released from the nanoformulation at pH 7.4"/>
   <result pre="superior biodistribution to the liver was observed compared to non-modified" exact="silibinin" post="following oral administration in rats [15]. The orally applicable"/>
   <result pre="in Huh-7 Cells Harboring Subgenomic RepliconsJ. Virol.2003775487549210.1128/JVI.77.9.5487-5492.200312692249 15.LiuC.H.LinC.C.HsuW.C.ChungC.Y.LinC.C.JasseyA.ChangS.P.TaiC.J.TaiC.J.ShieldsJ.et al.Highly bioavailable" exact="silibinin" post="nanoparticles inhibit HCV infectionGut2017661853186110.1136/gutjnl-2016-31201927436270 16.DebRoyS.HiragaN.ImamuraM.HayesC.N.AkamatsuS.CaniniL.PerelsonA.S.PohlR.T.PersianiS.UprichardS.L.Hepatitis C virus dynamics and"/>
   <result pre="expression in uPA-SCID chimeric mice with humanized livers during intravenous" exact="silibinin" post="monotherapyJ. Viral Hepat.20162370871710.1111/jvh.1255127272497 17.WagonerJ.MorishimaC.GrafT.N.OberliesN.H.TeissierE.PécheurE.-I.TavisJ.E.PolyakS.J.Differential In Vitro Effects of Intravenous"/>
   <result pre="Among Korean American ParentsJ. Immigr. Minor. Heal.20172094395010.1007/s10903-017-0609-128639095 31.UmetsuT.InoueJ.KogureT.KakazuE.NinomiyaM.IwataT.TakaiS.NakamuraT.SanoA.ShimosegawaT.Inhibitory effect of" exact="silibinin" post="on hepatitis B virus entryBiochem. Biophys. Rep.201814202510.1016/j.bbrep.2018.03.00329872730 32.WuY.-F.FuS.-L.KaoC.-H.YangC.-W.LinC.-H.HsuM.-T.TsaiT.-F.Chemopreventive Effect"/>
   <result pre="37.MalaguarneraG.BertinoG.ChisariG.MottaM.VecchioM.VacanteM.CaraciF.GrecoC.DragoF.NunnariG.et al.Silybin supplementation during HCV therapy with pegylated interferon-α plus" exact="ribavirin" post="reduces depression and anxiety and increases work abilityBMC Psychiatry20161639810.1186/s12888-016-1115-z27842532"/>
   <result pre="Hepatitis C Viremia Induced by Intravenous Silibinin Plus RibavirinGastroenterology200913739039110.1053/j.gastro.2009.02.08719486953 42.RutterK.ScherzerT.-M.BeinhardtS.KerschnerH.StättermayerA.F.HoferH.Popow-KrauppT.Steindl-MundaP.FerenciP.Intravenous" exact="silibinin" post="as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin"/>
   <result pre="on-treatment non-responders to pegylated interferon/ribavirin combination therapyAntivir. Ther.2011161327133310.3851/IMP194222155914 43.BiermerM.SchlosserB.FülöpB.van BömmelF.BrodzinskiA.HeyneR.KellerK.SarrazinC.BergT.High-dose" exact="silibinin" post="rescue treatment for HCV-infected patients showing suboptimal virologic response"/>
   <result pre="prevention of hepatitis C virus (HCV) liver graft reinfection by" exact="silibinin" post="mono-therapyJ. Hepatol.20105295195210.1016/j.jhep.2010.02.00220413176 47.BeinhardtS.Rasoul-RockenschaubS.ScherzerT.M.FerenciP.Silibinin monotherapy prevents graft infection after orthotopic"/>
   <result pre="CJ. Hepatol.20115459159210.1016/j.jhep.2010.09.00921106270 48.EurichD.BahraM.BergT.Boas-KnoopS.BiermerM.NeuhausR.NeuhausP.NeumannU.Treatment of hepatitis C-virus-reinfection after liver transplant with" exact="silibinin" post="in nonresponders to pegylated interferon-based therapyExp. Clin. Transplant.201191621605016 49.AghemoA.BhooriS.De"/>
   <result pre="Graft ReinfectionHepat. Mon.20121241141410.5812/hepatmon.613522879832 50.KnapsteinJ.WörnsA.M.GalleP.R.ZimmermannT.Combination therapy with silibinin, pegylated interferon and" exact="ribavirin" post="in a patient with hepatitis C virus genotype 3"/>
   <result pre="after liver transplantation: A case reportJ. Med. Case Rep.2014825710.1186/1752-1947-8-25725047566 51.MariñoZ.CrespoG.D’AmatoM.BrambillaN.GiacovelliG.RovatiL.CostaJ.NavasaM.FornsX.Intravenous" exact="silibinin" post="monotherapy shows significant antiviral activity in HCV-infected patients in"/>
   <result pre="peri-transplantation periodJ. Hepatol.20135841542010.1016/j.jhep.2012.09.03423063567 52.RendinaM.D’AmatoM.CastellanetaA.CastellanetaN.M.BrambillaN.GiacovelliG.RovatiL.RizziS.F.ZappimbulsoM.BringiottiR.S.et al.Antiviral activity and safety profile of" exact="silibinin" post="in HCV patients with advanced fibrosis after liver transplantation:"/>
   <result pre="trialTranspl. Int.20142769670410.1111/tri.1232424673819 53.BárcenaR.MorenoA.Rodriguez-GandiaM.A.AlbillosA.ArocenaC.BlesaC.García-HozF.GrausJ.NuñoJ.López-HervásP.et al.Safety and anti-HCV effect of prolonged intravenous" exact="silibinin" post="in HCV genotype 1 subjects in the immediate liver"/>
   <result pre="56.PayerB.ReibergerT.RutterK.BeinhardtS.StaettermayerA.Peck-RadosavljevicM.FerenciP.Successful HCV eradication and inhibition of HIV replication by intravenous" exact="silibinin" post="in an HIV–HCV coinfected patientJ. Clin. Virol.20104913113310.1016/j.jcv.2010.07.00620709593 57.BraunD.RauchA.DurischN.EberhardN.AnagnostopoulosA.LedergerberB.MetznerK.J.BöniJ.WeberR.FehrJ.Efficacy of"/>
   <result pre="in an HIV–HCV coinfected patientJ. Clin. Virol.20104913113310.1016/j.jcv.2010.07.00620709593 57.BraunD.RauchA.DurischN.EberhardN.AnagnostopoulosA.LedergerberB.MetznerK.J.BöniJ.WeberR.FehrJ.Efficacy of lead-in" exact="silibinin" post="and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected"/>
   <result pre="biopharmaceutical evaluation of silymarin using SMEDDSArch. Pharmacal. Res.200730828910.1007/BF02977782 60.WuJ.-W.LinL.-C.HungS.-C.ChiC.-W.TsaiT.-H.Analysis of" exact="silibinin" post="in rat plasma and bile for hepatobiliary excretion and"/>
   <result pre="of pharmacokineticsJ. Ethnopharmacol.200912118519310.1016/j.jep.2008.10.03619041708 62.WeyhenmeyerR.MascherH.BirkmayerJ.Study on dose-linearity of the pharmacokinetics of" exact="silibinin" post="diastereomers using a new stereospecific assayInt. J. Clin. Pharmacol."/>
   <result pre="silybin glycosidesPhytother. Res.200216Suppl. 1S33S3910.1002/ptr.79611933137 66.MiraL.SilvaM.MansoC.Scavenging of reactive oxygen species by" exact="silibinin" post="dihemisuccinateBiochem. Pharmacol.19944875375910.1016/0006-2952(94)90053-18080448 67.MaheshwariH.AgarwalR.PatilC.KatareO.P.Preparation and pharmacological evaluation of silibinin liposomesArzneimittelforschung20035342042710.1055/s-0031-129713012872613"/>
   <result pre="species by silibinin dihemisuccinateBiochem. Pharmacol.19944875375910.1016/0006-2952(94)90053-18080448 67.MaheshwariH.AgarwalR.PatilC.KatareO.P.Preparation and pharmacological evaluation of" exact="silibinin" post="liposomesArzneimittelforschung20035342042710.1055/s-0031-129713012872613 68.KumarN.RaiA.ReddyN.D.RajP.V.JainP.DeshpandeP.MathewG.KuttyN.G.UdupaN.RaoC.M.Silymarin liposomes improves oral bioavailability of silybin besides"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6515236\results\search\drugs\results.xml">
   <result pre="pyruvate, 100 U mL−1 of penicillin, 0.1 mg mL−1 of" exact="streptomycin" post="and 0.5 µg mL−1 of fungizone (Amphotericin B) (PAN"/>
   <result pre="FBS, 100 U mL−1 of penicillin, 0.1 mg mL−1 of" exact="streptomycin" post="and 1% of non-essential amino acid (NEAA). Primary human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6527025\results\search\drugs\results.xml">
   <result pre="in blocking autophagosome degradation. They verified this fact by using" exact="amantadine" post="hydrochloride, an inhibitor of M2 ion channel activity, which"/>
   <result pre="molecular mechanisms of selenium nanoparticles, modified on their surfaces by" exact="amantadine" post="(Se@AM), and their effects on IAV infection, demonstrated caspase-3"/>
   <result pre="de MeloGR, de FreitasCS, et alThe clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replication. Sci Rep. 2017;7:40920. [15]DuffyMR, ChenTH,"/>
   <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathways. Int J Nanomedicine. 2018;13:2005–2016.29662313"/>
   <result pre="activation. Virol J. 2015;12:77.25976933 [335]PeymaniP, GhavamiS, YeganehB, et alEffect of" exact="chloroquine" post="on some clinical and biochemical parameters in non-response chronic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6532103\results\search\drugs\results.xml">
   <result pre="MO, USA), 100 IU/ml penicillin (Lonza, Basel, Switzerland), 100 μg/ml" exact="streptomycin" post="(Lonza), 2 mM glutamine (Lonza), 1.5 mg/ml sodium bicarbonate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6555921\results\search\drugs\results.xml">
   <result pre="the experiment was stopped by humane killing (excessive injection of" exact="pentobarbital" post="sodium) with subsequent post mortem analysis. Consent for publication"/>
   <result pre="and review of the literature for pediatric age groupsInfection201038323123510.1007/s15010-010-0013-420358246 6.HaydenFGJenningsLRobsonRSchiffGJacksonHRanaBMcClellandGIpeDRobertsNWardPOral" exact="oseltamivir" post="in human experimental influenza B infectionAntivir Ther20005320521311075941 7.SatoMSaitoRSatoITanabeNShobugawaYSasakiALiDSuzukiYSakaiTOgumaTTsukadaHGejyoFSuzukiHEffectiveness of"/>
   <result pre="oseltamivir in human experimental influenza B infectionAntivir Ther20005320521311075941 7.SatoMSaitoRSatoITanabeNShobugawaYSasakiALiDSuzukiYSakaiTOgumaTTsukadaHGejyoFSuzukiHEffectiveness of" exact="oseltamivir" post="treatment among children with influenza a or B virus"/>
   <result pre="Niigata City, JapanTohoku J Exp Med2008214211312010.1620/tjem.214.11318285668 8.SugayaNMitamuraKYamazakiMTamuraDIchikawaMKimuraKKawakamiCKisoMItoMHatakeyamaSKawaokaYLower clinical effectiveness of" exact="oseltamivir" post="against influenza B contrasted with influenza a infection in"/>
   <result pre="a virus infection: results of a placebo-controlled trial of intravenous" exact="zanamivir" post="treatmentJ Infect Dis1999180358659310.1086/31493810438343 22.BodewesRRimmelzwaanGFOsterhausADAnimal models for the preclinical evaluation"/>
   <result pre="preclinical evaluation of candidate influenza vaccinesExpert Rev Vaccines201091597210.1586/erv.09.14820021306 23.RoweTBannerDFarooquiANgDCKelvinAARubinoSHuangSSHFangYKelvinDJIn vivo" exact="ribavirin" post="activity against severe pandemic H1N1 influenza a/Mexico/4108/2009J Gen Virol201091122898290610.1099/vir.0.024323-020797971"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6555941\results\search\drugs\results.xml">
   <result pre="serum (FBS) (GIBCO, Carlsbad, CA), 2 mM l-glutamine, 100 μg/ml" exact="streptomycin" post="and 100 units/ml penicillin (Invitrogen, Carlsbad, CA) at 37"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6560071\results\search\drugs\results.xml">
   <result pre="at the end of the experiment, were euthanized with sodium" exact="pentobarbital" post="(Dolethal, Vetoquinol, Madrid, Spain). Recombinant Subviral Particles (RSPs) RSPs"/>
   <result pre="at the end of the experiment, were euthanized with sodium" exact="pentobarbital" post="(Dolethal, Vetoquinol, Madrid, Spain). Author Contributions EE-R, UH, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6560413\results\search\drugs\results.xml">
   <result pre="associated with steroids, the former requires a heavier treatment including" exact="methotrexate" post="[176]. At the opposite end of the spectrum, accounts"/>
   <result pre="[148,238,239]. As discussed above, in case of chronic inflammatory rheumatism," exact="methotrexate" post="treatment might be necessary [176]. Several studies have searched"/>
   <result pre="trials conducted until now have either failed, such as for" exact="chloroquine" post="[248,249], or have been inconclusive because of small test"/>
   <result pre="been inconclusive because of small test groups, such as for" exact="ribavirin" post="[250]. Pentosan polysulfate has shown efficiency against cartilage damage"/>
   <result pre="randomized parallel-group studyIndian J. Rheumatol.200949410110.1016/S0973-3698(10)60189-6 240.WolfS.TaylorA.ZaidA.FreitasJ.HerreroL.J.RaoS.SuhrbierA.ForwoodM.R.BucalaR.MahalingamS.Inhibition of IL-1β signaling by" exact="anakinra" post="shows a critical role for bone loss in experimental"/>
   <result pre="Rev. Anti-Infect. Ther.20191712210.1080/14787210.2019.159559130449226 248.De LamballerieX.BoissonV.ReynierJ.-C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 249.RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.et al.Paradoxical Effect of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6563376\results\search\drugs\results.xml">
   <result pre="antiviral treatment is associated with the greatest clinical benefit, standard-dose" exact="oseltamivir" post="(75 mg twice daily in adults) for enteric administration is"/>
   <result pre="while awaiting results of influenza diagnostic tests. • Enterically administered" exact="oseltamivir" post="is recommended for influenza patients except for those with"/>
   <result pre="intravenous peramivir); cap-dependent endonuclease inhibitor (baloxavir marboxil); and adamantanes (e.g.," exact="amantadine" post="and rimantadine) (Table 4). NAIs and baloxavir have activity"/>
   <result pre="healthy outpatients. Meta-analyses of randomized placebo-controlled clinical trials of early" exact="oseltamivir" post="treatment of influenza in pediatric and adult outpatients have"/>
   <result pre="(12 years or older) ≥80 kg Single dose of 80 mg *FDA-approved oral" exact="oseltamivir" post="treatment dose for infants 14 days and older and less"/>
   <result pre="twice daily. The American Academy of Pediatrics has recommended an" exact="oseltamivir" post="treatment dose of 3.5 mg/kg orally twice daily for infants"/>
   <result pre="conducted in hospitalized influenza patients to establish the efficacy of" exact="oseltamivir" post="or other NAIs. A number of observational studies have"/>
   <result pre="did not [72]. A cohort study of early versus late" exact="oseltamivir" post="treatment reported a significant reduction in mortality and median"/>
   <result pre="Greece [78]. One French study reported delays in initiation of" exact="oseltamivir" post="treatment prescribed to hospitalized influenza patients and suggested empiric"/>
   <result pre="prescribed to hospitalized influenza patients and suggested empiric administration of" exact="oseltamivir" post="treatment in the emergency department for patients being admitted"/>
   <result pre="inhibitors are limited in critically ill influenza patients. Enterically administered" exact="oseltamivir" post="is the preferred treatment for most hospitalized patients, given"/>
   <result pre="most hospitalized patients, given the lack of data for intravenous" exact="peramivir" post="in this population. The use of inhaled zanamivir is"/>
   <result pre="for intravenous peramivir in this population. The use of inhaled" exact="zanamivir" post="is not recommended in in critically ill patients due"/>
   <result pre="bronchospasm in patients with underlying lung disease. Studies indicate that" exact="oseltamivir" post="administered orally or via oro/naso-gastric tube is well absorbed"/>
   <result pre="ambulatory patients [80]. Similarly, several observational studies indicate that enteric" exact="oseltamivir" post="reaches comparable plasma concentrations to non-critically ill patients in"/>
   <result pre="dosing [80, 88–92]. Of note, studies also suggest that increased" exact="oseltamivir" post="dosing does not provide additional clinical benefit in obese"/>
   <result pre="[49, 98]. For patients who cannot tolerate or absorb enteric" exact="oseltamivir" post="due to gastric stasis, malabsorption, or other gastrointestinal processes,"/>
   <result pre="due to gastric stasis, malabsorption, or other gastrointestinal processes, intravenous" exact="peramivir" post="may be an alternative [99, 100]; however, studies have"/>
   <result pre="100]; however, studies have not identified an advantage for intravenous" exact="peramivir" post="in comparison with enteric oseltamivir [101]. Notably, a randomized"/>
   <result pre="identified an advantage for intravenous peramivir in comparison with enteric" exact="oseltamivir" post="[101]. Notably, a randomized trial conducted in three influenza"/>
   <result pre="in three influenza seasons found similar clinical outcomes between IV" exact="peramivir" post="and enteric oseltamivir in hospitalized adult influenza patients [102];"/>
   <result pre="seasons found similar clinical outcomes between IV peramivir and enteric" exact="oseltamivir" post="in hospitalized adult influenza patients [102]; a separate trial"/>
   <result pre="separate trial did not identify significant additional clinical benefit of" exact="peramivir" post="in combination with standard-of-care therapy (which often included an"/>
   <result pre="randomized controlled trial also found similar clinical benefit between enteric" exact="oseltamivir" post="and intravenous peramivir in hospitalized influenza patients [104]. In"/>
   <result pre="also found similar clinical benefit between enteric oseltamivir and intravenous" exact="peramivir" post="in hospitalized influenza patients [104]. In 2018, a novel"/>
   <result pre="showed similar clinical benefit to 5 days of twice-daily oral" exact="oseltamivir" post="[105]. However, because these studies were limited to patients"/>
   <result pre="tract at 24 h compared with those receiving placebo or oral" exact="oseltamivir" post="[105]. However, it is unknown whether this reduction in"/>
   <result pre="assess the efficacy and safety of baloxavir in combination with" exact="oseltamivir" post="versus oseltamivir monotherapy in hospitalized influenza patients is currently"/>
   <result pre="efficacy and safety of baloxavir in combination with oseltamivir versus" exact="oseltamivir" post="monotherapy in hospitalized influenza patients is currently enrolling participants"/>
   <result pre="triple-combination antiviral drug (TCAD) therapy, which combines amantadine, ribavirin, and" exact="oseltamivir" post="for treatment of influenza in critically ill and high-risk"/>
   <result pre="to date have not shown a benefit of TCAD over" exact="oseltamivir" post="monotherapy [125–127]. Several novel antiviral compounds are in various"/>
   <result pre="variety of other immunomodulatory agents for treatment of influenza, including" exact="celecoxib" post="[137], statins, etanercept, pioglitazone, azithromycin [138], and interferons [139]."/>
   <result pre="for treatment of influenza, including celecoxib [137], statins, etanercept, pioglitazone," exact="azithromycin" post="[138], and interferons [139]. Conclusions Influenza vaccination can reduce"/>
   <result pre="should be tested by molecular assay. Antiviral treatment with standard-dose" exact="oseltamivir" post="delivered orally or enterally by oro or naso-gastric tube"/>
   <result pre="Care201620133710.1186/s13054-016-1512-127770828 55.Katzen J, Kohn R, Houk JL, Ison MG. Early" exact="oseltamivir" post="after hospital admission is associated with shortened hospitalization: a"/>
   <result pre="admission is associated with shortened hospitalization: a five-year analysis of" exact="oseltamivir" post="timing and clinical outcomes. Clin Infect Dis. 2018. 10.1093/cid/ciy860."/>
   <result pre="a meta-analysis of randomised controlled trialsLancet201538599791729173710.1016/S0140-6736(14)62449-125640810 66.MaloshREMartinETHeikkinenTBrooksWAWhitleyRJMontoASEfficacy and safety of" exact="oseltamivir" post="in children: systematic review and individual patient data meta-analysis"/>
   <result pre="randomized controlled trialsClin Infect Dis201866101492150010.1093/cid/cix104029186364 67.HibaVChowersMLevi-VinogradIRubinovitchBLeiboviciLPaulMBenefit of early treatment with" exact="oseltamivir" post="in hospitalized patients with documented 2009 influenza A (H1N1):"/>
   <result pre="influenza cases over six seasonsEpidemiol Infect2018146779980810.1017/S095026881800066329606178 74.RodriguezADiazEMartin-LoechesIet al.Impact of early" exact="oseltamivir" post="treatment on outcome in critically ill patients with 2009"/>
   <result pre="E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early" exact="oseltamivir" post="treatment on mortality in critically ill patients with different"/>
   <result pre="of print]. 79.MartinotMGronnwaldAGerberVet al.Analysis of delays in the prescription of" exact="oseltamivir" post="in hospitals and potential for improvementMed Mal Infect2019491596210.1016/j.medmal.2018.10.00830446349 80.ArianoRESitarDSZelenitskySAet"/>
   <result pre="for improvementMed Mal Infect2019491596210.1016/j.medmal.2018.10.00830446349 80.ArianoRESitarDSZelenitskySAet al.Enteric absorption and pharmacokinetics of" exact="oseltamivir" post="in critically ill patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet"/>
   <result pre="critically ill patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet al.Pharmacokinetics of" exact="oseltamivir" post="and oseltamivir carboxylate in critically ill patients receiving continuous"/>
   <result pre="patients with pandemic (H1N1) influenzaCMAJ2010182435736310.1503/cmaj.09212720159892 81.EylerRFHeungMPlevaMet al.Pharmacokinetics of oseltamivir and" exact="oseltamivir" post="carboxylate in critically ill patients receiving continuous venovenous hemodialysis"/>
   <result pre="continuous venovenous hemodialysis and/or extracorporeal membrane oxygenationPharmacotherapy201232121061106910.1002/phar.115123208833 82.EylerRFKleinKCMuellerBAThe pharmacokinetics of" exact="oseltamivir" post="and oseltamivir carboxylate in a critically ill pediatric patient"/>
   <result pre="hemodialysis and/or extracorporeal membrane oxygenationPharmacotherapy201232121061106910.1002/phar.115123208833 82.EylerRFKleinKCMuellerBAThe pharmacokinetics of oseltamivir and" exact="oseltamivir" post="carboxylate in a critically ill pediatric patient receiving extracorporeal"/>
   <result pre="hemodialysisJ Pediatr Pharmacol Ther201217217317623118670 83.GiraudCManceauSOualhaMet al.High levels and safety of" exact="oseltamivir" post="carboxylate plasma concentrations after nasogastric administration in critically ill"/>
   <result pre="intensive care unitAntimicrob Agents Chemother201155143343510.1128/AAC.00813-1020937783 84.KromdijkWSikmaMAvan den BroekMPBeijnenJHHuitemaADde LangeDWPharmacokinetics of" exact="oseltamivir" post="carboxylate in critically ill patients: each patient is uniqueIntensive"/>
   <result pre="membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of" exact="oseltamivir" post="carboxylate in critically ill patients with pandemic (H1N1) influenzaTher"/>
   <result pre="Clin Pharm Ther201742666167110.1111/jcpt.1263628948652 88.LeeNHuiDSZuoZet al.A prospective intervention study on higher-dose" exact="oseltamivir" post="treatment in adults hospitalized with influenza a and B"/>
   <result pre="B infectionsClin Infect Dis201357111511151910.1093/cid/cit59724046309 89.NoelZRBastinMLTMontgomeryAAFlanneryAHComparison of high-dose versus standard dose" exact="oseltamivir" post="in critically ill patients with influenzaJ Intensive Care Med2017321057457710.1177/088506661663864926992784"/>
   <result pre="East Asia Infectious Disease Clinical Research NEffect of double dose" exact="oseltamivir" post="on clinical and virological outcomes in children and adults"/>
   <result pre="trialBMJ2013346f303910.1136/bmj.f303923723457 92.DixitRKhandakerGHayPet al.A randomized study of standard versus double dose" exact="oseltamivir" post="for treating influenza in the communityAntivir Ther201520768969810.3851/IMP280724912485 93.PaiMPLodiseTPJrOseltamivir and"/>
   <result pre="oseltamivir for treating influenza in the communityAntivir Ther201520768969810.3851/IMP280724912485 93.PaiMPLodiseTPJrOseltamivir and" exact="oseltamivir" post="carboxylate pharmacokinetics in obese adults: dose modification for weight"/>
   <result pre="influenza: a clinical perspectiveCurr Opin Infect Dis201831652052630299356 99.WhitleyRLaughlinACarsonSet al.Single dose" exact="peramivir" post="for the treatment of acute seasonal influenza: integrated analysis"/>
   <result pre="efficacy and safety from two placebo-controlled trialsAntivir Ther201520770971910.3851/IMP287425318121 100.IsonMGFraizJHellerBet al.Intravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsAntivir Ther201419434936110.3851/IMP268023985625 101.LeeJParkJHJwaHKimYHComparison"/>
   <result pre="and meta-analysisYonsei Med J201758477878510.3349/ymj.2017.58.4.77828540991 102.IsonMGHuiDSClezyKet al.A clinical trial of intravenous" exact="peramivir" post="compared with oral oseltamivir for the treatment of seasonal"/>
   <result pre="102.IsonMGHuiDSClezyKet al.A clinical trial of intravenous peramivir compared with oral" exact="oseltamivir" post="for the treatment of seasonal influenza in hospitalized adultsAntivir"/>
   <result pre="influenza in hospitalized adultsAntivir Ther201318565166110.3851/IMP244223111657 103.de JongMDIsonMGMontoASet al.Evaluation of intravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsClin Infect Dis20145912e172e18510.1093/cid/ciu63225115871"/>
   <result pre="hospitalized patientsClin Infect Dis20145912e172e18510.1093/cid/ciu63225115871 104.NakamuraSMiyazakiTIzumikawaKet al.Efficacy and safety of intravenous" exact="peramivir" post="compared with oseltamivir in high-risk patients infected with influenza"/>
   <result pre="Dis20145912e172e18510.1093/cid/ciu63225115871 104.NakamuraSMiyazakiTIzumikawaKet al.Efficacy and safety of intravenous peramivir compared with" exact="oseltamivir" post="in high-risk patients infected with influenza A and B"/>
   <result pre="A (H7N9) viral pneumoniaCrit Care Med2016446e318e32810.1097/CCM.000000000000161626934144 125.BeigelJHBaoYBeelerJet al.Oseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
   <result pre="Med2016446e318e32810.1097/CCM.000000000000161626934144 125.BeigelJHBaoYBeelerJet al.Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus" exact="oseltamivir" post="monotherapy for the treatment of influenza: a multicentre, double-blind,"/>
   <result pre="phase 2 trialLancet Infect Dis201717121255126510.1016/S1473-3099(17)30476-028958678 126.SeoSEnglundJANguyenJTet al.Combination therapy with amantadine," exact="oseltamivir" post="and ribavirin for influenza A infection: safety and pharmacokineticsAntivir"/>
   <result pre="trialLancet Infect Dis201717121255126510.1016/S1473-3099(17)30476-028958678 126.SeoSEnglundJANguyenJTet al.Combination therapy with amantadine, oseltamivir and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther201318337738610.3851/IMP247523264438 127.KimWYYoung"/>
   <result pre="of Medicine, 2018. 131.GenentechIA study of MHAA4549A in combination with" exact="oseltamivir" post="versus oseltamivir in participants with severe influenza a infection."/>
   <result pre="2018. 131.GenentechIA study of MHAA4549A in combination with oseltamivir versus" exact="oseltamivir" post="in participants with severe influenza a infection. ClinicalTrialsgov [internet]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6563844\results\search\drugs\results.xml">
   <result pre="and diluted in either water, phosphate buffer saline (PBS), or" exact="dimethyl sulfoxide" post="(DMSO, Sigma) to stock concentrations of 0.5 M, and"/>
   <result pre="following doses used in all mouse experiments: 50 mg/kg/day for" exact="oseltamivir" post="phosphate, 40 mg/kg/day for naltrexone, 100 mg/kg/day gallium nitrate,"/>
   <result pre="virus strains were treated orally every 8 h with either" exact="oseltamivir" post="(2.5 mg/kg, Roche) or dextromethorphan (2 mg/kg, Procter, &amp;amp;"/>
   <result pre="infection, or left untreated. For infection, animals were anesthetized with" exact="ketamine" post="and medetomidine (2/0.2 mg/kg), and then inoculated intranasally with"/>
   <result pre="left untreated. For infection, animals were anesthetized with ketamine and" exact="medetomidine" post="(2/0.2 mg/kg), and then inoculated intranasally with 1 ×"/>
   <result pre="activity at a 10-fold lower concentration (Table 1). Adenosine triphosphate," exact="etidronic acid," post="N-acetyl-D-glucosamine, L-glutamic acid, thalidomide, amiloride, and dacarbazine had no"/>
   <result pre="A/Mexico/InDRE4487/2009 (H1N1pdm09) were included in the study. The neuraminidase inhibitor" exact="oseltamivir" post="carboxylate was used as a positive control. Using the"/>
   <result pre="setup with 10-fold decreasing drug concentrations starting at 500 μM," exact="oseltamivir" post="carboxylate completely inhibited replication of all three strains at"/>
   <result pre="ranged from around 10-fold for gallium nitrate to 100-fold for" exact="naltrexone" post="and ketotifen, and around 1,000-fold for dextromethorphan. While the"/>
   <result pre="drug concentrations, again starting at 500 μM, the EC50 of" exact="oseltamivir" post="carboxylate ranged between 5 and 200 nM, with PR8"/>
   <result pre="MDCK cells using an MTT assay. While the SI for" exact="oseltamivir" post="carboxylate was between 2,000 and 100,000, the SI for"/>
   <result pre="still lowered lung viral titers around 8- to 10-fold, while" exact="naltrexone" post="and gallium nitrate treatments had no significant effect (Figure"/>
   <result pre="infection. In this series of experiments, the inhibitory effect of" exact="ketotifen" post="alone was even less pronounced, and there was no"/>
   <result pre="even less pronounced, and there was no additive effect when" exact="ketotifen" post="and dextromethorphan were combined. Combination of each of the"/>
   <result pre="dextromethorphan were combined. Combination of each of the drugs with" exact="oseltamivir" post="resulted in a slight, but non-significant increase in inhibition,"/>
   <result pre="combined, the inhibitory effect was significantly higher than that of" exact="oseltamivir" post="alone (Figure 3B), suggesting a modest benefit of combination"/>
   <result pre="oral dextromethorphan formulation at a dose of 2 mg/kg, or" exact="oseltamivir" post="solution at a dose of 2.5 mg/kg. This schedule"/>
   <result pre="twice daily for weight loss, temperature, and clinical signs. While" exact="oseltamivir" post="phosphate treatment resulted in a 10-fold reduction in nasal"/>
   <result pre="whereas there was no reduction in body weight in the" exact="oseltamivir" post="group (Figure 4B). In the control group, clinical signs"/>
   <result pre="4C). Even though the effect was less pronounced compared to" exact="oseltamivir" post="phosphate treatment, which only resulted in a minimal clinical"/>
   <result pre="of viral titers in vitro, but also in mice. While" exact="ketotifen" post="blocks histamine H1 receptors and the release of inflammatory"/>
   <result pre="to opioid-containing cough suppressants (51, 52). The antiviral properties of" exact="ketotifen" post="may thus be associated with its anti-inflammatory effect (39),"/>
   <result pre="differences in disease severity and pathological and virological parameters. While" exact="oseltamivir" post="reduced viral load and clinical disease, and prevented weight"/>
   <result pre="warranted to evaluate if combination treatment increases the efficacy of" exact="oseltamivir" post="or other virus-targeting drugs, especially when treatment is started"/>
   <result pre="technologies. J Clin Pharmacol. (2014) 54:719–31. 10.1002/jcph.29924691877 10.IntharathepPLaohpongspaisanCRungrotmongkolTLoisruangsinAMalaisreeMDechaPet al.. How" exact="amantadine" post="and rimantadine inhibit proton transport in the M2 protein"/>
   <result pre="Clin Pharmacol. (2014) 54:719–31. 10.1002/jcph.29924691877 10.IntharathepPLaohpongspaisanCRungrotmongkolTLoisruangsinAMalaisreeMDechaPet al.. How amantadine and" exact="rimantadine" post="inhibit proton transport in the M2 protein channel. J"/>
   <result pre="viruses. Antimicrobial Agents Chemother. (2010) 54:2517–24. 10.1128/AAC.01739-0920350949 29.TomieAAzoguIYuL. Effects of" exact="naltrexone" post="on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice."/>
   <result pre="10.1093/cvr/cvp04319189960 41.SmeeDFHurstBLWongMHBaileyKWMorreyJD. Effects of double combinations of amantadine, oseltamivir, and" exact="ribavirin" post="on influenza A (H5N1) virus infections in cell culture"/>
   <result pre="and cell survival. Cell. (2007) 131:596–610. 10.1016/j.cell.2007.08.03617981125 58.OchiaiHKurokawaMNiwayamaS. Influence of" exact="trifluoperazine" post="on the late stage of influenza virus infection in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6585104\results\search\drugs\results.xml">
   <result pre="[58]. HEV infected individuals can be treated with the antiviral" exact="ribavirin" post="and for prophylaxis, a human vaccine, at least against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6593267\results\search\drugs\results.xml">
   <result pre="only licensed drug for the treatment of this virus. However," exact="ribavirin" post="is difficult to use, costly, and teratogenic, and there"/>
   <result pre="these patients, particularly the youngest. The administration of tetracyclines and" exact="chloramphenicol" post="can lead to severe adverse events; ketolides and streptogramins"/>
   <result pre="these deaths was directly ascribed to the ADV infection. However," exact="cidofovir" post="is not licensed for the treatment of ADV; this"/>
   <result pre="http://www.fast-trackdiagnostics.com/human-line/products/ftd-respiratory-pathogens-33/ (accessed February 5, 2019). GanapathiL.ArnoldA.JonesS.PattersonA.GrahamD.HarperM.et al. (2016). Use of" exact="cidofovir" post="in pediatric patients with adenovirus infection. Version2. F1000Res.5:75810.12688/f1000research.8374.127239277 GardinerS."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6610691\results\search\drugs\results.xml">
   <result pre="DENV 3 neurovirulence in mice found that increased levels of" exact="nitric oxide" post="synthase 2 could be the cause of the death"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6620336\results\search\drugs\results.xml">
   <result pre="mM L-glutamine, 1X non-essential amino acids, 100 units/ml penicillin, 100 µg/ml" exact="streptomycin" post="and 2 µg amphotericin B. C6/36 cells were incubated at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6627469\results\search\drugs\results.xml">
   <result pre="vaccines.7 In case of an epidemic, neuraminidase inhibitors such as" exact="oseltamivir" post="or zanamivir can be used to reduce the illness"/>
   <result pre="case of an epidemic, neuraminidase inhibitors such as oseltamivir or" exact="zanamivir" post="can be used to reduce the illness symptoms and"/>
   <result pre="spacers for enhanced multivalency effects.41−43 Compound 3 is a polymeric" exact="dextran" post="scaffold44 for comparison with the &quot;small�? molecule scaffolds 1"/>
   <result pre="of 8. cNot determined. din the presence of 10 μM" exact="oseltamivir" post="carboxylate. First to note is that the inhibition with"/>
   <result pre="were run in the presence of 10 μM neuraminidase inhibitor" exact="oseltamivir" post="carboxylate (OC) to inhibit the neuraminidase that could potentially"/>
   <result pre="μM) of 14, 15, and 12 in the presence of" exact="oseltamivir" post="carboxylate, with the same experiments without the NA inhibitor."/>
   <result pre="first, similar degrees of inhibition and, second, no effect of" exact="oseltamivir" post="carboxylate. Besides the BLI assay, also a hemagglutination inhibition"/>
   <result pre="could be observed between HA inhibitor 15 and NA inhibitor" exact="oseltamivir" post="carboxylate. Low nanomolar concentrations of each showed little effect,"/>
   <result pre="it was remarkable that no effect of the NA inhibitor" exact="oseltamivir" post="carboxylate was observed. Furthermore, in the infection inhibition assay"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6627559\results\search\drugs\results.xml">
   <result pre="the effect of interferons (Table 1). For a long time," exact="rimantadine" post="and amantadine were very actively used to treat the"/>
   <result pre="of interferons (Table 1). For a long time, rimantadine and" exact="amantadine" post="were very actively used to treat the flu. Leibbrand"/>
   <result pre="the virus particle to the cytoplasm of the cell. Thus," exact="rimantadine" post="becomes an obstacle between the influenza virus and the"/>
   <result pre="undecivir/RelenzaTM), M2 channel blockers, and fusion inhibitors (umifenovir/ArbidolTM). Zanamivir and" exact="oseltamivir" post="have shown lower than expected efficacy in clinical trials."/>
   <result pre="factors [41]. According to the literature, sulphated polysaccharides (fucoidans, galactofucans," exact="dextran" post="sulphates, carrageenans, sulphated chitosans, synthetic polyvinyl, and polyethylene sulphates)"/>
   <result pre="other drugs. Thus, a combined intranasal spray, including carrageenan and" exact="zanamivir" post="(an NA inhibitor) was proposed by Morokutti-Kurz et al."/>
   <result pre="efficacy of in vivo and in vitro intranasal administration of" exact="zanamivir" post="in different doses for the prevention and treatment of"/>
   <result pre="complex preparation were non-toxic at the highest concentration (400 μg/mL" exact="zanamivir" post="and 533 μg/mL carrageenan). The effectiveness of the suppression"/>
   <result pre="substances depended on the virus strain. The IC50 value for" exact="zanamivir" post="ranged from 0.18 µg/mL for H5N1 and 22.97 µg/mL"/>
   <result pre="µg/mL to 118.40 µg/mL for H1N1 and H7N7, respectively. Thus," exact="zanamivir" post="and carrageenan target different strains of influenza virus to"/>
   <result pre="two drugs was suggested [69]. For more than 50 years," exact="xylometazoline" post="has been used to relieve vasoconstriction and oedema of"/>
   <result pre="treated with fucoidan. The authors proposed the combined treatment with" exact="oseltamivir" post="and fucoidan, because in this case there was no"/>
   <result pre="when treating only with oseltamivir. Combined treatment with fucoidan and" exact="oseltamivir" post="was thus recommended by the authors as a new"/>
   <result pre="to the control group (p &amp;lt; 0.05). When treated with" exact="oseltamivir" post="alone, 90% of the mice survived. All influenza viruses"/>
   <result pre="Infection, From Now and Into the FutureFront. Immunol.20189194610.3389/fimmu.2018.0194630250466 36.MartyF.M.Vidal-PuigserverJ.ClarkC.GuptaS.K.MerinoE.GarotD.ChapmanM.J.JacobsF.Rodriguez-NoriegaE.HusaP.et al.Intravenous" exact="zanamivir" post="or oral oseltamivir for hospitalised patients with influenza: An"/>
   <result pre="and Into the FutureFront. Immunol.20189194610.3389/fimmu.2018.0194630250466 36.MartyF.M.Vidal-PuigserverJ.ClarkC.GuptaS.K.MerinoE.GarotD.ChapmanM.J.JacobsF.Rodriguez-NoriegaE.HusaP.et al.Intravenous zanamivir or oral" exact="oseltamivir" post="for hospitalised patients with influenza: An international, randomised, double-blind,"/>
   <result pre="the Murine ModelPLoS ONE201510e012879410.1371/journal.pone.012879426053018 69.GrafC.Bernkop-SchnurchA.EqyedA.CollerC.Prieschl-GrassauerA.Morokutti-KurzM.Development of a nasal spray containing" exact="xylometazoline" post="hydrochloride and iota-carrageenan for the symptomatic relief of nasal"/>
   <result pre="(nausea and vomiting; diarrhea, abdominal bloating, and fecal incontinence) Rimantadine," exact="amantadine" post="M2 channel blockers. An inhibitor of the early stage"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6629778\results\search\drugs\results.xml">
   <result pre="Asia (Sung et al., 2016). Similarly, in the same year," exact="lovastatin" post="showed no power to address efficacy in Vietnam (Whitehorn"/>
   <result pre="infection that exhibits human monocyte infection, multiple cytokine production and" exact="dexamethasone" post="immunomodulation. Mem. Inst. Oswaldo Cruz102, 983–990. 10.1590/S0074-0276200700080001418209938 RetallackH.Di LulloE.AriasC.KnoppK."/>
   <result pre="FreitasC. S.RochaN.HoelzL. V.MirandaM.et al. (2017). The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replication. Sci. Rep.7:4092010.1038/srep4092028098253 SahuR.VermaR.JainA.GargR. K.SinghM. K.MalhotraH."/>
   <result pre="Dis.11, 315–330. 29062856 SimanjuntakY.LiangJ. J.LeeY. L.LinY. L. (2015). Repurposing of" exact="prochlorperazine" post="for use against dengue virus infection. J. Infect. Dis.211,"/>
   <result pre="T.HsuS. T.ChangD. M.et al.. (2011). Immunosuppressive effects and mechanisms of" exact="leflunomide" post="in dengue virus infection of human dendritic cells. J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6630949\results\search\drugs\results.xml">
   <result pre="virus polymerase PB2 subunitAntimicrob. Agents Chemother.2015591569158210.1128/AAC.04623-1425547360 98.SmeeD.F.BarnardD.L.JonesS.M.Activities of JNJ63623872 and" exact="oseltamivir" post="against influenza A H1N1pdm and H3N2 virus infections in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6631207\results\search\drugs\results.xml">
   <result pre="in silico and in vitro approaches suggested the potential of" exact="sofosbuvir" post="(SFB), an antiviral prodrug clinically used against hepatitis C"/>
   <result pre="used a drug repurposing strategy to identify the macrolide antibiotic" exact="azithromycin" post="(AZT) as a potential anti-ZIKV drug. AZT was found"/>
   <result pre="(NMDA) glutamate receptor blockers, including MK-801, agmatine sulfate, ifenprodil, and" exact="memantine" post="(ME), in models of ZIKV-induced neuronal damage both in"/>
   <result pre="Our group has recently evaluated whether the TNF-α neutralizing antibody" exact="infliximab" post="(IFX) (20 μg/day) is able to prevent long-term consequences"/>
   <result pre="performed by Xu and colleagues also identified the anti-helmintic drug" exact="niclosamide" post="as a powerful antiviral drug against ZIKV, being able"/>
   <result pre="(Xu et al., 2016). In another study, two doses of" exact="niclosamide" post="(on embryonic days 3 and 5; 50 mg/kg) were"/>
   <result pre="viral entry in cells [122]. However, time-of-addition experiments indicate that" exact="niclosamide" post="is still effective even after viral cell invasion is"/>
   <result pre="which must be closely evaluated before clinical studies [127]. Therefore," exact="niclosamide" post="seems like a good candidate for management of infection"/>
   <result pre="6.7. Amodiaquine Another interesting antimalarial quinine with anti-ZIKV activity is" exact="amodiaquine" post="(AQ). A high-content screening study identified its ability to"/>
   <result pre="several viruses such as measles and rabies [131]. One specific" exact="adenosine" post="analog, NITD008, has been proven effective against a number"/>
   <result pre="An example in translational research suggesting the possible use of" exact="bumetanide" post="in newbornFront. Neurol.201343610.3389/fneur.2013.0003623596438 15.StagniF.GiacominiA.GuidiS.CianiE.BartesaghiR.Timing of therapies for Down syndrome:"/>
   <result pre="Fetal-like Organoids and Adult BrainCell Stem Cell201721274283.e510.1016/j.stem.2017.06.01728736217 81.HanY.MesplèdeT.XuH.QuanY.WainbergM.A.The antimalarial drug" exact="amodiaquine" post="possesses anti-ZIKA virus activitiesJ. Med. Virol.20189079680210.1002/jmv.2503129315671 82.RetallackH.DiE.AriasC.KnoppK.A.LaurieM.T.Zika virus cell"/>
   <result pre="in Different Cell ModelsViruses2016832210.3390/v8120322 85.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika Virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 86.LiC.ZhuX.JiX.QuanquinN.DengY.-Q.TianM.AliyariR.ZuoX.YuanL.AfridiS.K.et al.Chloroquine,"/>
   <result pre="and implications to assess efficacy of antiviralsAntiviral Res.2017145828610.1016/j.antiviral.2017.07.01028736077 91.KimJ.A.SeongR.K.KumarM.ShinO.S.Favipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of zika"/>
   <result pre="compounds using a cell-based, high-throughput screen assayAntivir. Res.2017138475610.1016/j.antiviral.2016.11.01827919709 98.YinZ.ChenY.-L.SchulW.WangQ.-Y.GuF.DuraiswamyJ.KondreddiR.R.NiyomrattanakitP.LakshminarayanaS.B.GohA.et al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc. Natl. Acad. Sci. USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="Neuroepithelial Stem Cells and Radial GliaCell Rep.2016162576259210.1016/j.celrep.2016.08.03827568284 102.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntiviral Res.201713713414010.1016/j.antiviral.2016.11.02327902933 103.SacramentoC.Q.De MeloG.R.De FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The"/>
   <result pre="infectionAntiviral Res.201713713414010.1016/j.antiviral.2016.11.02327902933 103.SacramentoC.Q.De MeloG.R.De FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 104.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.ZhangN.N.TianM.HaoJ.N.et al.A peptide-based viral"/>
   <result pre="PregnancyAvailable online: https://clinicaltrials.gov/ct2/show/NCT02683005(accessed on 19 March 2019) 107.WiwanitkitS.WiwanitkitV.Doubled dosage of" exact="sofosbuvir" post="is expected for inhibiting Zika virus infectionAsian Pac. J."/>
   <result pre="and transplacental pharmacokinetics of azithromycinAm. J. Obstet. Gynecol.200318871471810.1067/mob.2003.14112634646 115.JaruratanasirikulS.HortiwakulR.TantisarasartT.PhuenpathomN.TussanasunthornwongS.Distribution of" exact="azithromycin" post="into brain tissue, cerebrospinal fluid, and aqueous humor of"/>
   <result pre="triclabendazole and oxamniquineInt. J. Risk Saf. Med.200820113122 122.KaoJ.C.HuangFuW.C.TsaiT.T.HoM.R.JhanM.K.ShenT.J.TsengP.C.WangY.T.LinC.F.The antiparasitic drug" exact="niclosamide" post="inhibits dengue virus infection by interfering with endosomal acidification"/>
   <result pre="nanoformulated antihelminthic, niclosamide, in ovarian cancerOncotarget201678993900610.18632/oncotarget.711326848771 124.ZhangX.ZhangY.ZhangT.ZhangJ.WuB.Significantly enhanced bioavailability of" exact="niclosamide" post="through submicron lipid emulsions with or without PEG-lipid: A"/>
   <result pre="FonsecaB.A.L.Chloroquine use improves dengue-related symptomsMem. Inst. Oswaldo Cruz201310859659910.1590/S0074-0276201300050001023903975 129.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against today’s diseasesLancet"/>
   <result pre="Dis.2003372272710.1016/S1473-3099(03)00806-514592603 130.TaylorW.R.J.WhiteN.J.Antimalarial Drug ToxicityDrug Saf.200427256110.2165/00002018-200427010-0000314720085 131.De ClercqE.BergstromD.E.JohnA.H.Broad-spectrum antiviral activity of" exact="adenosine" post="analoguesAntivir. Res.1984411913310.1016/0166-3542(84)90012-36476818 132.LoM.K.ShiP.-Y.ChenY.-L.FlintM.SpiropoulouC.F.In vitro antiviral activity of adenosine analog"/>
   <result pre="activity of adenosine analoguesAntivir. Res.1984411913310.1016/0166-3542(84)90012-36476818 132.LoM.K.ShiP.-Y.ChenY.-L.FlintM.SpiropoulouC.F.In vitro antiviral activity of" exact="adenosine" post="analog NITD008 against tick-borne flavivirusesAntivir. Res.2016130464910.1016/j.antiviral.2016.03.01327016316 133.EyerL.ZouharováD.ŠirmarováJ.FojtíkováM.ŠtefánikM.HaviernikJ.NenckaR.de ClercqE.RůžekD.Antiviral activity"/>
   <result pre="NITD008 against tick-borne flavivirusesAntivir. Res.2016130464910.1016/j.antiviral.2016.03.01327016316 133.EyerL.ZouharováD.ŠirmarováJ.FojtíkováM.ŠtefánikM.HaviernikJ.NenckaR.de ClercqE.RůžekD.Antiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6631698\results\search\drugs\results.xml">
   <result pre="promising target for anti-EV-D68 drugs. The selective serotonin reuptake inhibitor" exact="fluoxetine" post="(Prozac) inhibits human enterovirus by targeting protein 2C and"/>
   <result pre="protein 2C and interfering with viral RNA replication [10]. However," exact="fluoxetine" post="has proven to be ineffective in improving the neurologic"/>
   <result pre="reducing the paralysis in the mice, and immunosuppressants such as" exact="dexamethasone" post="worsened the motor impairment and increased mortality [65,66]. In"/>
   <result pre="Gen. Virol.2012931952195810.1099/vir.0.043935-022694903 10.UlfertsR.van der LindenL.ThibautH.J.LankeK.H.W.LeyssenP.CoutardB.De PalmaA.M.CanardB.NeytsJ.van KuppeveldF.J.M.Selective serotonin reuptake inhibitor" exact="fluoxetine" post="inhibits replication of human enteroviruses B and D by"/>
   <result pre="protein 2CAntimicrob. Agents Chemother.2013571952195610.1128/AAC.02084-1223335743 11.MessacarK.SillauS.HopkinsS.E.OttenC.Wilson-MurphyM.WongB.SantoroJ.D.TreisterA.BainsH.K.TorresA.et al.Safety, tolerability, and efficacy of" exact="fluoxetine" post="as an antiviral for acute flaccid myelitisNeurology201810.1212/WNL.0000000000006670 12.MusharrafiehR.MaC.ZhangJ.HuY.DiesingJ.M.MartyM.T.WangJ.Validating Enterovirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6631769\results\search\drugs\results.xml">
   <result pre="100 µL of the transformed bacterial suspension was spread on" exact="ampicillin" post="containing Luria-Bertani (LB) Agar plate and incubated for 16"/>
   <result pre="above with 20 ng of pMP-H1/RBD plasmid. Individual colonies from" exact="ampicillin" post="containing LB Agar plate were picked and incubated in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6642581\results\search\drugs\results.xml">
   <result pre="prognosis of severe Influenza a infectionJ Infect Dis2018217342843710.1093/infdis/jix47529325098 23.JiaXLiuBBaoLLvQLiFLiHet al.Delayed" exact="oseltamivir" post="plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury"/>
   <result pre="severe Influenza a infectionJ Infect Dis2018217342843710.1093/infdis/jix47529325098 23.JiaXLiuBBaoLLvQLiFLiHet al.Delayed oseltamivir plus" exact="sirolimus" post="treatment attenuates H1N1 virus-induced severe lung injury correlated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6648004\results\search\drugs\results.xml">
   <result pre="indicatorsActa Paul Enferm2017307379 47FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRet al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis201913e000707230699122"/>
   <result pre="Dis201913e000707230699122 48FerreiraACReisPAFreitasCSSacramentoCQVillas Bôas HoelzLBastosMMet al.Beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob Agents Chemother201963e01389-1830455237 49IslanGADuránMCacicedoMLNakazatoGKobayashiRKMartinezDSet al.Nanopharmaceuticals"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6653809\results\search\drugs\results.xml">
   <result pre="C.ReisP. A.DelvecchioR.et al.. (2019). Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivo. PLoS Negl. Trop."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6657620\results\search\drugs\results.xml">
   <result pre="viruses. In mice, it has a better therapeutic effect than" exact="oseltamivir" post="(47). Antibodies Against the HA Stem Anti-HA stem broadly"/>
   <result pre="between sialic acid and the newborn virions. Neuraminidase inhibitors like" exact="oseltamivir" post="act by inhibiting the last step and causing virus"/>
   <result pre="and highly conserved N-terminal ectodomain (M2e, 23 aa). Antiviral drugs" exact="amantadine" post="and rimantadine target M2, blocking the proton influx into"/>
   <result pre="conserved N-terminal ectodomain (M2e, 23 aa). Antiviral drugs amantadine and" exact="rimantadine" post="target M2, blocking the proton influx into the virion"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6659212\results\search\drugs\results.xml">
   <result pre="For blood-meal preparation, rabbit blood was washed and mixed with" exact="adenosine" post="5’-triphosphate (ATP) (5 × 10−3 M) (Sigma-Aldrich, St. Louis, MO, USA)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6661876\results\search\drugs\results.xml">
   <result pre="progeny from the cell surface. Three FDA-approved NAIs are oseltamivir," exact="peramivir" post="and zanamivir.[16] Wang et al.[17] performed a multicenter, retrospective"/>
   <result pre="NAI combination treatment and monotherapy or between standard-dose and double-dose" exact="oseltamivir" post="treatment. Another antiviral drug is the adamantanes inhibitors, including"/>
   <result pre="treatment. Another antiviral drug is the adamantanes inhibitors, including adamantanes," exact="rimantadine" post="and amantadine. They target the M2 ion channel of"/>
   <result pre="most dynamic mutations. The NA R292K mutation is associated with" exact="oseltamivir" post="resistance. Due to the constant variability of the virus"/>
   <result pre="et al.[27] found that high-dose corticosteroid therapy (&amp;gt; 150 mg/d" exact="methylprednisolone" post="or equivalent) significantly increased both 30-day and 60-day mortality,"/>
   <result pre="impact was observed for low-to-moderate doses of corticosteroids (25–150 mg/d" exact="methylprednisolone" post="or equivalent). Li et al.[28] found that patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6663013\results\search\drugs\results.xml">
   <result pre="surveillance. One strain of influenza virus A(H1N1)pdm09 was resistant to" exact="oseltamivir" post="and had the H275Y amino acid substitution in the"/>
   <result pre="to anti-neuraminidase drugs Susceptibility of influenza viruses to neuraminidase inhibitors" exact="oseltamivir" post="and zanamivir was tested in fluorescent neuraminidase inhibition assay"/>
   <result pre="drugs Susceptibility of influenza viruses to neuraminidase inhibitors oseltamivir and" exact="zanamivir" post="was tested in fluorescent neuraminidase inhibition assay with 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic"/>
   <result pre="were able to hemagglutinate in the presence of 20 nM" exact="oseltamivir" post="[8]. These particular strains were selected for the HI"/>
   <result pre="H275Y substitution was previously associated with highly reduced inhibition by" exact="oseltamivir" post="and reduced or highly reduced inhibition by peramivir of"/>
   <result pre="inhibition by oseltamivir and reduced or highly reduced inhibition by" exact="peramivir" post="of A(H1N1)pdm09 viruses (according to the criteria of the"/>
   <result pre="with resistance of influenza A(H1N1)pdm09 viruses to the NA inhibitor" exact="zanamivir" post="were identified. Genetic analysis of A(H3N2) influenza virus was"/>
   <result pre="An association of this mutation with a slight increase in" exact="oseltamivir" post="IC50 (less than 10 times) was shown for A(H1N1)"/>
   <result pre="the course of the monitoring of seasonal influenza, sensitivity to" exact="oseltamivir" post="and zanamivir of 87 isolated influenza viruses A and"/>
   <result pre="of the monitoring of seasonal influenza, sensitivity to oseltamivir and" exact="zanamivir" post="of 87 isolated influenza viruses A and B was"/>
   <result pre="A(H3N2) and B influenza viruses were sensitive to anti-neuraminidase drugs" exact="oseltamivir" post="and zanamivir. Among the 47 A(H1N1)pdm09 analyzed isolates, only"/>
   <result pre="one strain, A/Samara/117868/2018, was characterized by highly reduced sensitivity to" exact="oseltamivir" post="with IC50 = 97.6 nМ and median value being"/>
   <result pre="0.1–1.5 nM [13]. Susceptibility of this one oseltamivir-resistant strain to" exact="zanamivir" post="was normal. Genetic analysis revealed the presence of the"/>
   <result pre="NA of this strain, which is associated with resistance to" exact="oseltamivir" post="of A(H1N1) pdm09 viruses. Discussion In this study the"/>
   <result pre="isolated from a lethal case of influenza was resistant to" exact="oseltamivir" post="while remaining susceptible to zanamivir; it contained the H275Y"/>
   <result pre="only one strain of A(H1N1)pdm09 influenza virus was resistant to" exact="oseltamivir" post="and had the H275Y amino acid substitution in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6664529\results\search\drugs\results.xml">
   <result pre="and ground glass opacification. Although OP was suspected and 1 mg/kg" exact="methylprednisolone" post="was used, the patient’s condition didn’t improved considerably. An"/>
   <result pre="specimen was compatible with OP. The patient was treated with" exact="methylprednisolone" post="1.5 mg/kg for 5 days. ECMO was weaned on day 15,"/>
   <result pre="primary influenza pneumonia was controlled. And a steroid dose of" exact="methylprednisolone" post="1.5 mg/kg may be suggested for treatment of OP associated"/>
   <result pre="virus of sputum specimen turned out to be positive and" exact="oseltamivir" post="phosphate was initiated (150 mg twice daily for 2 weeks after"/>
   <result pre="(2.52 from serum sample and 1.21 from BALF sample), vancomycin," exact="imipenem" post="cilastatin and caspofungin were applied. Hydrocortisone 300 mg daily for"/>
   <result pre="from serum sample and 1.21 from BALF sample), vancomycin, imipenem" exact="cilastatin" post="and caspofungin were applied. Hydrocortisone 300 mg daily for 3 days"/>
   <result pre="sample and 1.21 from BALF sample), vancomycin, imipenem cilastatin and" exact="caspofungin" post="were applied. Hydrocortisone 300 mg daily for 3 days was also"/>
   <result pre="condition did not improve after 5 days of daily use of" exact="methylprednisolone" post="80 mg, histological examination was done via open lung biopsy"/>
   <result pre="surrounding lung parenchyma. The therapy of steroid was changed to" exact="methylprednisolone" post="120 mg (1.5 mg/kg) for 5 days, 80 mg for 7 days, 40 mg for"/>
   <result pre="over three weeks. Steroid was the main treatment, varying from" exact="prednisolone" post="30 mg/day to methylprednisolone 500 mg/day pulse therapy, with or without"/>
   <result pre="Steroid was the main treatment, varying from prednisolone 30 mg/day to" exact="methylprednisolone" post="500 mg/day pulse therapy, with or without tapering. Most patients"/>
   <result pre="A Respiratory failure Consolidation NR OLB OP Intravenous steroids and" exact="azathioprine" post="Survival Fujita, 2007 [6] 38 F A NR Consolidation"/>
   <result pre="show rapid responding to steroids. The introduced initial dose is" exact="prednisone" post="0.5–1.0 mg/kg, with tapering over 6–12 month. However, up to one-third"/>
   <result pre="period. For the current patient with avian influenza H7N9-associated OP," exact="methylprednisolone" post="80 mg (1 mg/kg) daily was applied for 5 days with tapering"/>
   <result pre="the confirmation of histological examination, steroid dose was increased to" exact="methylprednisolone" post="120 mg (1.5 mg/kg) daily for 5 days. And OP was finally"/>
   <result pre="may responsive to a brief course (weeks) of moderate-to-high dose" exact="prednisone" post="therapy. To the best of our knowledge, this was"/>
   <result pre="controlling of primary influenza pneumonia. And a steroid dose of" exact="methylprednisolone" post="1.5 mg/kg maybe suggested for treatment of OP associated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6669691\results\search\drugs\results.xml">
   <result pre="fetal bovine serum (10%; Gibco, Carlsbad, CA, USA), penicillin and" exact="streptomycin" post="(1000 units/mL and 100 µg/mL, respectively; Invitrogen, Carlsbad, CA,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6679168\results\search\drugs\results.xml">
   <result pre="only a small proton channel activity that is insensitive to" exact="amantadine" post="[92]. Those authors proposed that the CM2 protein is"/>
   <result pre="in a hydrophilic pocket [56,123,124]. Together with its close derivative," exact="rimantadine" post="(Rim, Flumadine), they are the only licensed antiviral drugs"/>
   <result pre="BM2 inhibitors have been identified to date. The lack of" exact="amantadine" post="inhibition of BM2 may be explained by differences in"/>
   <result pre="inhibition of CFTR: (i) addition of M2 ion channel inhibitor" exact="amantadine" post="rescued CFTR expression and activity in Xenopus oocytes expressing"/>
   <result pre="reported to be affected by cardiac glycosides such as ouabain," exact="digoxin" post="and lanatoside C, which express antiviral activity against influenza"/>
   <result pre="influenza virus M2 proton channel is formed by a single" exact="tryptophan" post="residueJ. Biol. Chem.2002277398803988610.1074/jbc.M20658220012183461 38.PintoL.H.LambR.A.The M2 proton channels of influenza"/>
   <result pre="from a structure in a lipid bilayerScience201033050951210.1126/science.119175020966252 56.CadyS.D.Schmidt-RohrK.WangJ.SotoC.S.DegradoW.F.HongM.Structure of the" exact="amantadine" post="binding site of influenza M2 proton channels in lipid"/>
   <result pre="NMRScience201033050550810.1126/science.119171420966251 77.WilliamsJ.K.ZhangY.Schmidt-RohrK.HongM.PH-dependent conformation, dynamics, and aromatic interaction of the gating" exact="tryptophan" post="residue of the influenza M2 proton channel from solid-state"/>
   <result pre="80.MarkiewiczB.N.LemminT.ZhangW.AhmedI.A.JoH.FiorinG.TroxlerT.DeGradoW.F.GaiF.Infrared and fluorescence assessment of the hydration status of the" exact="tryptophan" post="gate in the influenza A M2 proton channelPCCP201618289392895010.1039/C6CP03426H27725984 81.LinC.W.MensaB.Barniol-XicotaM.DeGradoW.F.GaiF.Activation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6681032\results\search\drugs\results.xml">
   <result pre="medicines are currently available. These include (i) the neuraminidase inhibitors" exact="oseltamivir" post="(Roche), zanamivir (GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate"/>
   <result pre="currently available. These include (i) the neuraminidase inhibitors oseltamivir (Roche)," exact="zanamivir" post="(GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo);"/>
   <result pre="These include (i) the neuraminidase inhibitors oseltamivir (Roche), zanamivir (GlaxoSmithKline)," exact="peramivir" post="(BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo); (ii) the"/>
   <result pre="laninamivir octanoate (Daiichi Sankyo); (ii) the M2 ion channel blockers" exact="rimantadine" post="(Sun Pharma) and amantadine (Endo); (iii) favipiravir (Toyama Chemical),"/>
   <result pre="(ii) the M2 ion channel blockers rimantadine (Sun Pharma) and" exact="amantadine" post="(Endo); (iii) favipiravir (Toyama Chemical), which inhibits the ribonucleic"/>
   <result pre="called 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA, 1, Figure 1) [5,6,7,8,9,10,11,12,13]. EFdA is an" exact="adenosine" post="derivative armed with an ethynyl group at the 4′-position,"/>
   <result pre="Activities We intended to analyze the anti-influenza activity of 4′-ethynyl" exact="adenosine" post="derivatives, namely EFdA (1), 4′-ethynyl-2′-deoxyadenosine (EdA, 2) [13], and"/>
   <result pre="EFdA analogs may work against the influenza virus [25]. The" exact="adenosine" post="derivatives of compounds 1–3 were evaluated for their in"/>
   <result pre="Silyl–Hilbert–Johnson reaction between adenine and acetate 12 furnished the desired" exact="adenosine" post="derivative 13 in a 73% yield [33,34]. After the"/>
   <result pre="was treated with Bu3SnH and azobisisobutyronitrile (AIBN) to generate deoxy" exact="adenosine" post="derivative 16 in an 86% yield [35,36]. The deprotection"/>
   <result pre="to generate phosphate monoester. EdA (2) was easily hydrolyzed by" exact="adenosine" post="deaminase to generate the corresponding inactive inosine derivative [6,11,37]."/>
   <result pre="easily hydrolyzed by adenosine deaminase to generate the corresponding inactive" exact="inosine" post="derivative [6,11,37]. However, EdAP, which has the same scaffold"/>
   <result pre="cycloSal phosphate group could prevent the conversion of EdAP by" exact="adenosine" post="deaminase, or other unknown mechanisms may exist. 3. Materials"/>
   <result pre="resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: Comparative sequential passage study with lamivudine, tenofovir," exact="emtricitabine" post="and BMS-986001Antivir. Ther.20141917918910.3851/IMP269724162098 17.WuV.H.SmithR.A.MasoumS.RaugiD.N.BaS.SeydiM.GroblerJ.A.GottliebG.S.MK-8591 (4′-ethynyl-2-fluoro-2′-deoxyadenosine) exhibits potent activity against"/>
   <result pre="HIV-2 mutants in cultureAntimicrob. Agents Chemother.201761e00744-1710.1128/AAC.00744-1728559249 18.NjendaD.T.AralaguppeS.G.SinghK.RaoR.SönnerborgA.SarafianosS.G.NeogiU.Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine," exact="tenofovir" post="alafenamide and second-generation NNRTIs across diverse HIV-1 subtypesJ. Antimicrob."/>
   <result pre="a function of EdAP (filled circle and solid line) or" exact="oseltamivir" post="carboxylate (open square and dashed line) concentrations, as indicated."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6688121\results\search\drugs\results.xml">
   <result pre="al.. Sub-epidemics explain localized high prevalence of reduced susceptibility to" exact="rilpivirine" post="in treatment-naive HIV-1-infected patients: subtype and geographic compartmentalization of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6689137\results\search\drugs\results.xml">
   <result pre="cohort, they showed that IOP reduced after intravitreal injection of" exact="cidofovir" post="in an attempt to treat retinal CMV.11 It is"/>
   <result pre="Another cohort showed a decrease in IOP in patients receiving" exact="cidofovir" post="via parenteral compared to CMV patients without the use"/>
   <result pre="aqueous humor dynamics in patients with AIDS treated with intravitreal" exact="cidofovir" post="(HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol. 1997;124(2):168–180. doi:10.1016/S0002-9394(14)70781-09262540"/>
   <result pre="13.AklerME, JohnsonDW, BurmanWJ, JohnsonSC. Anterior uveitis and hypotony after intravenous" exact="cidofovir" post="for the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105(4):651–657. doi:10.1016/S0161-6420(98)94019-29544639"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6689504\results\search\drugs\results.xml">
   <result pre="respective vector was cultured in yeast extract peptone medium containing" exact="kanamycin" post="(50 mg/L), rifampicin (50 mg/L), and gentamicin (50 mg/mL)"/>
   <result pre="cultured in yeast extract peptone medium containing kanamycin (50 mg/L)," exact="rifampicin" post="(50 mg/L), and gentamicin (50 mg/mL) at 28℃ for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6694824\results\search\drugs\results.xml">
   <result pre="harboring at least one plasmid were enriched by selection with" exact="puromycin" post="at 1.5 μg · ml−1 for 3 to 5 days and single-cell sorted"/>
   <result pre="35.BloomJD, GongLI, BaltimoreD2010Permissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistance. Science328:1272–1275. doi:10.1126/science.1187816.20522774 36.BrightRA, ShayDK, ShuB, CoxNJ, KlimovAI2006Adamantane resistance"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6695095\results\search\drugs\results.xml">
   <result pre="alleviated by interference of the viral proton channel activity by" exact="amantadine" post="treatment. As M1 and M2 are expressed from the"/>
   <result pre="cells infected with IAV carrying avian M segments, we used" exact="chloroquine" post="treatment followed by Western immunoblotting for LC3B I and"/>
   <result pre="cells infected with PR8 avian M viruses, then treatment with" exact="chloroquine" post="would not lead to a further increase in LC3B"/>
   <result pre="of these cells induces autophagy, then blocking their turnover with" exact="chloroquine" post="would result in heightened LC3B II over mock-infected, chloroquine-treated"/>
   <result pre="segments, precipitate a block in the autophagy pathway such that" exact="chloroquine" post="treatment cannot bring about further accumulation of autophagosomes. Ion"/>
   <result pre="PR8 avian M virus-infected cells, we inhibited channel activity with" exact="amantadine" post="[61]. Amantadine was added at 1 hpi and the"/>
   <result pre="and PR8 avian M virus-infected A549 cells. The timing of" exact="amantadine" post="addition was designed to avoid disruption of the early"/>
   <result pre="stronger for viruses possessing avian M segments. Interestingly, addition of" exact="amantadine" post="reversed the intracellular accumulation of LC3B II in both"/>
   <result pre="expression levels of M1 or M2 protein upon treatment with" exact="amantadine" post="(Fig 10A, 10B, 10C and 10D), but revealed a"/>
   <result pre="and incubated in the presence or absence of 200 μM" exact="amantadine" post="from 1 hpi. Cells were lysed at 8 hpi."/>
   <result pre="A549 cells in the presence or absence of 200 μM" exact="amantadine" post="for 8 h. (H) LC3B I and (I) LC3B"/>
   <result pre="was assessed using ordinary one-way ANOVA. To ensure that the" exact="amantadine" post="was working to prevent LC3B II accumulation through inhibition"/>
   <result pre="of M2 ion channel activity, we assessed the impact of" exact="amantadine" post="treatment on the inhibition of phagosome-lysosome fusion by chloroquine."/>
   <result pre="of M2 protein (Fig 10G–10I), indicating that the mechanism of" exact="amantadine" post="block of autophagosome accumulation was specifically mediated through interference"/>
   <result pre="Western immunoblot analyses obtained in A549 cells, we saw that" exact="amantadine" post="reduced the accumulation of LC3B-GFP within cytoplasmic puncta and"/>
   <result pre="the plasma membrane of infected cells (Fig 11). Of note," exact="amantadine" post="treatment did not alter levels or localization of M2"/>
   <result pre="and incubated in the presence or absence of 200 μM" exact="amantadine" post="from 1 hpi. Cells were fixed at 12 hpi"/>
   <result pre="mediate the observed block in autophagy, and that addition of" exact="amantadine" post="can reverse the autophagic phenotypes induced by both human"/>
   <result pre="avian M-encoding IAVs. Improved viral growth in the presence of" exact="amantadine" post="implicates autophagy block in viral growth restriction To test"/>
   <result pre="effect on viral growth of relieving the autophagy block with" exact="amantadine" post="treatment. Specifically, we evaluated single-cycle growth in A549 cells"/>
   <result pre="of the earliest steps of the viral life cycle. While" exact="amantadine" post="had no effect on growth of the PR8 NL09"/>
   <result pre="peak titers of growth than the avian-origin M segment, however" exact="amantadine" post="had no impact on the growth of the pH1N1"/>
   <result pre="with lysosomes in a proton channel-dependent fashion [66]. Surprisingly, however," exact="amantadine" post="treatment was also found to reduce LC3B II accumulation"/>
   <result pre="or nasal lavage, animals were sedated with a mixture of" exact="ketamine" post="(30 mg/kg) and xylazine (4 mg/kg). Virus used for"/>
   <result pre="Emory Integrated Cellular Imaging core facility. Drug treatments Where indicated," exact="chloroquine" post="(Invitrogen) was added to cell culture medium at a"/>
   <result pre="and incubated in the presence or absence of 60 μM" exact="chloroquine" post="from 1 hpi. Cells were lysed with whole cell"/>
   <result pre="On the mechanism of inhibition of influenza virus replication by" exact="amantadine" post="hydrochloride. J Gen Virol38: 97–110. 10.1099/0022-1317-38-1-97563896 62van WielinkR, HarmsenMM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6695206\results\search\drugs\results.xml">
   <result pre="hour at 37°C. Infected VERO cells were overlayed with 1%" exact="methylcellulose" post="mixed with DMEM medium supplemented with 2% FBS, and"/>
   <result pre="and incubated at 37°C for 32 to 36 hours. The" exact="methylcellulose" post="overlays were discarded by washing with 1X PBS, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6701881\results\search\drugs\results.xml">
   <result pre="1640 medium (Lonza) containing 100 IU/mL penicillin (Gibco), 100 µg/mL" exact="streptomycin" post="(Gibco), 10% FBS supplemented with 25 ng/mL interleukin-4 (IL-4)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6710328\results\search\drugs\results.xml">
   <result pre="RNA virus, by serially passaging PV in the presence of" exact="ribavirin" post="(Pfeiffer and Kirkegaard, 2003; Vignuzzi et al., 2006). The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6714416\results\search\drugs\results.xml">
   <result pre="shirts, pants, and hats) Wearing light-colored clothing Treat clothing with" exact="permethrin" post="Use of mosquito repellents-Icaridin has been used as the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6721381\results\search\drugs\results.xml">
   <result pre="of species through morphological observation, captured rats were narcotized by" exact="pentobarbital" post="sodium, then dissected and extracted lung tissue sterilely. Lung"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6724274\results\search\drugs\results.xml">
   <result pre="(sweat chloride concentration ≥ 60 mmol/L) and/or two CFTR gene mutations. None received" exact="palivizumab" post="because it is not used in our current practice."/>
   <result pre="immediate family environment. Half attended exclusively family daycare. None received" exact="palivizumab" post="and 22 patients (88%) were vaccinated against influenza virus."/>
   <result pre="palivizumab-free. The American Academy of Pediatrics recommends the use of" exact="palivizumab" post="in CF for targeted patients, particularly those with poor"/>
   <result pre="D, American Academy of Pediatrics Bronchiolitis Guidelines CUpdated guidance for" exact="palivizumab" post="prophylaxis among infants and young children at increased risk"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6728053\results\search\drugs\results.xml">
   <result pre="and 2% antibiotic/antimycotic solution with 10,000 units penicillin, 10 mg" exact="streptomycin" post="and 25μg amphotericin B per ml (Sigma- Aldrich) [25]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6729038\results\search\drugs\results.xml">
   <result pre="14 days. A CMG from France (2017) recommended the addition of" exact="amoxicillin" post="in adults to cover for risk of L. monocytogenes"/>
   <result pre="N. meningitides is the most likely pathogen, and addition of" exact="cloxacillin" post="if associated skin or umbilical cord infection for all"/>
   <result pre="cefotaxime) 3rd generation-cephalosporin (ceftriaxone^ or cefotaxime) plus a penicillin (amoxicillin," exact="ampicillin" post="or penicillin) Aminoglycoside (gentamicin) plus a penicillin (amoxicillin or"/>
   <result pre="NNF Norsk Nevrologisk Forening Many CMGs recommended the addition of" exact="vancomycin" post="[2, 5, 34–37, 39, 40] alternatively rifampicin [2, 5,"/>
   <result pre="the addition of vancomycin [2, 5, 34–37, 39, 40] alternatively" exact="rifampicin" post="[2, 5, 37, 39] if there is suspicion of"/>
   <result pre="(USA) and NICE (UK) gave different advice. The first recommended" exact="vancomycin" post="to everyone except neonates (&amp;lt; 28 days old) [44], whereas the"/>
   <result pre="neonates (&amp;lt; 28 days old) [44], whereas the CMG by NICE recommended" exact="vancomycin" post="to all returning travellers or those with recent prolonged"/>
   <result pre="monocytogenes. Most of the European CMGs recommended the addition of" exact="vancomycin" post="or rifampicin if decreased susceptibility to penicillin or third-generation"/>
   <result pre="of the European CMGs recommended the addition of vancomycin or" exact="rifampicin" post="if decreased susceptibility to penicillin or third-generation cephalosporin is"/>
   <result pre="The CMG by IDSA aimed at all global settings recommended" exact="vancomycin" post="to everyone beyond neonatal age [44], which highlights the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6731212\results\search\drugs\results.xml">
   <result pre="3.5 days (±SD 2.9), and 70% received antiviral treatment with" exact="oseltamivir" post="or zanamivir, of whom 28.7% received it within 48 hours"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6734352\results\search\drugs\results.xml">
   <result pre="Administration (FDA): matrix-2 (M2) protein ion channel blockers (such as" exact="amantadine" post="and rimantadine) and neuraminidase (NA) inhibitors (such as zanamivir"/>
   <result pre="as amantadine and rimantadine) and neuraminidase (NA) inhibitors (such as" exact="zanamivir" post="and oseltamivir) [7]. However, during the last years, there"/>
   <result pre="(Merck, Germany), 2 mM L-glutamine (Merck, Germany), and 100 U/ml penicillin and 100 μg/ml" exact="streptomycin" post="sulfate (Sigma-Aldrich, USA). Influenza A/Puerto Rico/8/34 (H1N1; PR8) was"/>
   <result pre="in this experiment. This assay was also carried out for" exact="oseltamivir" post="and soluble polyethylene glycol. At the indicated time of"/>
   <result pre="Cytotoxicity assay Cytotoxic effects of ZnO-NPs, ZnO-PEG-NPs, polyethylene glycol, and" exact="oseltamivir" post="on MDCK-SIAT1 cells were determined using the MTT assay."/>
   <result pre="MTT assay. As shown in Fig. 4, polyethylene glycol and" exact="oseltamivir" post="did not show significant cytotoxic effects toward MDCK-SIAT1 cells."/>
   <result pre="Cytotoxicity of ZnO-NPs (a), ZnO-PEG-NPs (b), polyethylene glycol (c), and" exact="oseltamivir" post="(d) on MDCK-SIAT1 cells. * Statistically significant (p &amp;lt; 0.05). **"/>
   <result pre="in 1.2 log10 TCID50 reduction (P &amp;lt; 0.0001). In our experiments," exact="oseltamivir" post="was used as a positive control for comparison of"/>
   <result pre="the post-exposure antiviral activity of ZnO-NPs, ZnO-PEG-NPs, polyethylene glycol, and" exact="oseltamivir" post="on the titer of H1N1 influenza virus by TCID50"/>
   <result pre="that the production of influenza virus was completely inhibited by" exact="oseltamivir" post="at the concentration of 75 μg/mL. Furthermore, the inhibition rate"/>
   <result pre="Lin et al., antiviral properties of selenium nanoparticles (SeNPs) and" exact="zanamivir" post="modified selenium nanoparticles (Se@ZNV) against H1N1 influenza virus investigated,"/>
   <result pre="has a higher antiviral activity compared to the SeNPs and" exact="zanamivir" post="alone [27]. Similarly, Li et al. conducted a study"/>
   <result pre="conducted a study to investigate antiviral capabilities of SeNPs and" exact="oseltamivir" post="surface-modified SeNPs (Se@OTV) against H1N1 influenza virus [28]. Their"/>
   <result pre="and sialic acid receptor on the host cell. Oseltamivir and" exact="zanamivir" post="are sialic acid analogues and neuraminidase inhibitors which prevents"/>
   <result pre="studies conducted by Lin et al. and Li et al.," exact="oseltamivir" post="and zanamivir modified selenium nanoparticles were used for evaluation"/>
   <result pre="by Lin et al. and Li et al., oseltamivir and" exact="zanamivir" post="modified selenium nanoparticles were used for evaluation of anti-influenza"/>
   <result pre="9.NguyenJTSmeeDFBarnardDLJulanderJGGrossMde JongMDet al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza a virusesPLoS"/>
   <result pre="al.Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with" exact="zanamivir" post="through p38 and JNK signaling pathwaysRSC Adv2017756352903529610.1039/C7RA06477B 28.LiYLinZGuoMXiaYZhaoMWangCet al.Inhibitory"/>
   <result pre="pathwaysRSC Adv2017756352903529610.1039/C7RA06477B 28.LiYLinZGuoMXiaYZhaoMWangCet al.Inhibitory activity of selenium nanoparticles functionalized with" exact="oseltamivir" post="on H1N1 influenza virusInt J Nanomedicine201712573310.2147/IJN.S14093928848350 29.MittalNMedhiBThe bird flu:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6743175\results\search\drugs\results.xml">
   <result pre="for the online and offline measurement of exhaled lower respiratory" exact="nitric oxide" post="and nasal nitric oxide, 2005. Am J Respir Crit"/>
   <result pre="offline measurement of exhaled lower respiratory nitric oxide and nasal" exact="nitric oxide," post="2005. Am J Respir Crit Care Med 2005;171:912–30. 19.IpMSKoFWLauACYuWCTangKSChooKChan-YeungMMUpdated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6746389\results\search\drugs\results.xml">
   <result pre="with 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml" exact="streptomycin" post="and non-essential amino acids (Lonza) in a humidified incubator"/>
   <result pre="(IAA-94, Cayman Chemical), 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB, Santa Cruz Biotechnology) and" exact="dimethyl sulfoxide" post="(DMSO, Fisher Chemical). Compound stocks were dissolved in DMSO"/>
   <result pre="to a 9-fold decrease in CHIKV-Fluc SGR replication. As expected," exact="ribavirin" post="also significantly lowered CHIKV-Fluc SGR replication 37-fold (p ≤"/>
   <result pre="27RothanHA, BahraniH, MohamedZ, TeohTC, ShankarEM, RahmanNA, et al.A combination of" exact="doxycycline" post="and ribavirin alleviated chikungunya infection. PloS one. 2015;10(5):e012636010.1371/journal.pone.012636025970853 28BriolantS,"/>
   <result pre="MohamedZ, TeohTC, ShankarEM, RahmanNA, et al.A combination of doxycycline and" exact="ribavirin" post="alleviated chikungunya infection. PloS one. 2015;10(5):e012636010.1371/journal.pone.012636025970853 28BriolantS, GarinD, ScaramozzinoN,"/>
   <result pre="viruses replication by antiviral compounds: synergistic effect of interferon-α and" exact="ribavirin" post="combination. Antiviral research. 2004;61(2):111–7. 14670584 29StaufferF, De MirandaJ, SchechterMC,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6749704\results\search\drugs\results.xml">
   <result pre="UK evidenceAddiction2011106111978198810.1111/j.1360-0443.2011.03515.x21615585 18.LawitzEPoordadFFPangPSHylandRHDingXMoHSymondsWTMcHutchisonJGMembrenoFESofosbuvir and ledipasvir fixed-dose combination with and without" exact="ribavirin" post="in treatment-naive and previously treated patients with genotype 1"/>
   <result pre="CNew England Journal of Medicine20133681455310.1056/NEJMoa120880923281975 21.GaneEJStedmanCAHylandRHDingXSvarovskaiaESubramanianGMSymondsWTMcHutchisonJGPangPSEfficacy of nucleotide polymerase inhibitor" exact="sofosbuvir" post="plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6751066\results\search\drugs\results.xml">
   <result pre="with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml" exact="streptomycin" post="sulfate (P/S) (Life Technologies). Canine MDCK cells were cultured"/>
   <result pre="DNA mixture was removed and MEM supplemented with 1 μg/ml N-tosyl-" exact="l-phenylalanine" post="chloromethyl ketone (TPCK)-treated trypsin (Sigma) added. Virus supernatant was"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6751421\results\search\drugs\results.xml">
   <result pre="bronchodilators along with supportive care for acute hepatitis-like vitamin K," exact="ursodeoxycholic acid," post="and multivitamin were started with close monitoring of liver"/>
   <result pre="urine, one broad-spectrum antibiotic was started which further escalated to" exact="meropenem" post="based on culture sensitivity report, but there was no"/>
   <result pre="and a low-dose cardioselective B1 adrenergic agent was started. Intravenous" exact="furosemide" post="was added to optimize intravascular volume. Nitrate was given."/>
   <result pre="was added to optimize intravascular volume. Nitrate was given. Initially" exact="ivabradine" post="was given, then a beta-blocker was added after spasm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6757286\results\search\drugs\results.xml">
   <result pre="2). Pigs [102] and mice [103, 104] intranasally administered with" exact="clodronate" post="liposome to deplete AMs have higher lung virus titers"/>
   <result pre="of defense and beyondAnnual Review of Immunology201432112115510.1146/annurev-immunol-032713-120216 191TuW.ZhengJ.LiuY.et al.The aminobisphosphonate" exact="pamidronate" post="controls influenza pathogenesis by expanding a γδ T cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6759257\results\search\drugs\results.xml">
   <result pre="under ADF-issued mosquito nets 57.1 (12/21) 82.4 (14/17) Awareness of" exact="permethrin" post="uniform and bed net treatment 100 (21/21) 100 (17/17)"/>
   <result pre="bed net treatment 100 (21/21) 100 (17/17) Use of ADF-recommended" exact="permethrin" post="treatment 0 (0/21) 0 (0/17) *Data are % (no."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6759472\results\search\drugs\results.xml">
   <result pre="infection groups. Mice were anesthetized intraperitoneally with a mixture of" exact="ketamine" post="(100 mg/kg body weight) and xylazine (5 mg/kg body"/>
   <result pre="through a 300 μm nitrocellulose mesh filter (EMDMilipore). Then, 26%" exact="dextran" post="(MW, 150 kDa) in isolation buffer was added to"/>
   <result pre="Hanks balanced salt solution in both chambers, and fluorescently tagged" exact="dextran" post="(FITC-Dextran, Sigma-Aldrich) of 10 kDa or 20 kDa was"/>
   <result pre="the transwell system was replaced with medium containing fluorescently tagged" exact="dextran" post="of either 20 kDa or 10 kDa (Figure 2A,"/>
   <result pre="the transwell system was replaced with medium containing fluorescently tagged" exact="dextran" post="(FD) of 20 kDa (upper panel) and 10 kDa"/>
   <result pre="changes. In our study, we used different molecular weight FITC-tagged" exact="dextran" post="molecules (10 kDa and 20 kDa) that were smaller"/>
   <result pre="by the limitations of measurements of endothelial permeability with fluorescent" exact="dextran" post="polymers. Another possibility may be lack in our in"/>
   <result pre="10.1016/j.jinf.2014.05.01024880028 NguyenD. K.MontesinosM. C.WilliamsA. J.KellyM.CronsteinB. N. (2003). Th1 cytokines regulate" exact="adenosine" post="receptors and their downstream signaling elements in human microvascular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6769590\results\search\drugs\results.xml">
   <result pre="(CAT), superoxide dismutase (SOD), glutathione (GSH), vitamin E, carotenoids, and" exact="ascorbic acid." post="Reactive oxygen species (ROS) are produced during viral infections"/>
   <result pre="variety of pathogens without altering the host cell viability. The" exact="nicotinamide" post="adenine dinucleotide phosphate (NADPH) oxidase enzyme complex of phagocytic"/>
   <result pre="patients as revealed by the decrease of antioxidant defense (selenium," exact="ascorbic acid," post="alpha-tocopherol, carotenoids, superoxide dismutase, glutathione, and glutathione peroxidase) and"/>
   <result pre="ROS-Mediated Cell DeathInt. J. Cell Biol.2014201410.1155/2014/46745224899897 52.PeterhansE.Reactive oxygen species and" exact="nitric oxide" post="in viral diseasesBiol. Trace Elem. Res.19975610711610.1007/BF027789869152514 53.BeckM.A.LevanderO.A.HandyJ.Selenium deficiency and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6770471\results\search\drugs\results.xml">
   <result pre="Med.1999411811959890017 136.ZhaoX.ChenF.-P.SullenderW.M.Respiratory syncytial virus escape mutant derived in vitro resists" exact="palivizumab" post="prophylaxis in cotton ratsVirology200431860861210.1016/j.virol.2003.10.01814972528 137.DeplancheM.LemaireM.MirandetteC.BonnetM.SchelcherF.MeyerG.In vivo evidence for quasispecies"/>
   <result pre="of Hepatitis B virus in patients with YMDD mutation and" exact="lamivudine" post="resistance may not predict the efficacy of lamivudine/adefovir rescue"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="1-part\PMC6771534\results\search\drugs\results.xml">
   <result pre="capable of interacting with caveolin�?1 to alter the activity of" exact="nitric oxide" post="synthase and limit the production of NO145 and that"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
